

CURRICULUM VITAE

Phoebe Rich, M.D.

phoeberichderm@aol.com

Address:

**Phoebe Rich Dermatology
Oregon Dermatology & Research Center**
2565 NW Lovejoy Street, Suite 200
Portland, Oregon 97210
(503) 226-3376
(503) 223-9567 clinic fax
(503) 224-9903 research fax

Medical License: 07/13/1985

Oregon State Board of Medical Examiners
MD14488

Board Certified: 10/89

American Board of Dermatology

Education: 06/84

M.D.
Oregon Health & Science University
Portland, Oregon

Post Graduate Training:

1984 – 1985

Internal Medicine Internship
Good Samaritan Hospital
Portland, Oregon

1986 – 1989

Resident: Department of Dermatology
Oregon Health & Science University
Portland, Oregon

Employment: 1989 – Present

Owner
Board-Certified Dermatologist
Principal Investigator
Phoebe Rich Dermatology
Oregon Dermatology & Research Center
2565 NW Lovejoy Street, Suite 200
Portland, Oregon 97210

2009 – Present

Adjunct Professor
Director Nail Disorder Clinic
Department of Dermatology at Oregon Health & Science University
2565 NW Lovejoy Street, Suite 200
Portland, Oregon 97210

Phoebe Rich, MD

08/FEB/2024

Honors and Awards/Accomplishments:

2018	Oregon Health & Science University, Department of Dermatology Dr. Jonathan Alexander Community Faculty Teaching Award
2016	Clark W. Finnerud Award Dermatology Foundation
2013	American Academy of Dermatology Presidential Citation 2013
2011	American Academy of Dermatology Physician's Leadership Program (Mastery Course CCL)
2009	American Academy of Dermatology Presidential Citation 2009
2007	Oregon Health and Science Alumna Association Clinical Faculty Teaching Award Oregon Health Sciences University
1980	Lange Medical Student Award Freshman Medical Student
1978	Tartar Foundation Fellowship Department of Biochemistry
1977	Heart Association Fellowship USC School of Medicine Division of Cardiology

Academic Appointments:

2008 – Present	Adjunct Professor Director of the Nail Disorder Clinic Department of Dermatology Oregon Health & Science University
1997 – 2007	Clinical Associate Professor OHSU
1994 – 1997	Clinical Assistant Professor of Dermatology OHSU
1989 – 1994	Clinical Instructor OHSU

Memberships/Organizations:

American Academy of Dermatology (AAD)

2011 – 2015	Board of Directors (AAD)
1989 – Present	(AAD) Fellow
2015	Member Communications
2004 – 2007	Education Slide Series Task Force
2004 – 2007	Task Force on Drugs and the Environment
1998 – 2002	Membership Committees
1997 – 2005	Telemedicine Task Force
1991 – 1993	Pamphlets Committee, AAD

AAD Advisory Board

2007 – 2011	Oregon Representative
2009	Executive Committee

American Dermatological Association (ADA)

2006 – Present	Member
2007 – 2008	ADA Program Committee

American Society Dermatologic Surgeons

1995 – Present	Member
----------------	--------

Council for Nail Disorders

1995 – Present	Board of Directors
1999 – 2000	President
1997	Vice-President
1995	Charter member
1994 – 2007	Scientific Advisory Board

European Academy of Dermatology and Venereology

2016 – Present	Member
----------------	--------

European Nail Society

2000 – Present	Member
----------------	--------

Eczema Society for Science and Education

1992 – Present	Member
1992 – 1997	Board of Directors

International Conference on Nail Disorders

2019	Charter Member
------	----------------

International Society of Dermatology

2000 – Present	Member
----------------	--------

Dermatology Foundation

1989 – Present	Member Leaders Society
2009	Annenberg Sustaining Member

2002	Annenberg Society
1994 – 1996	Oregon State Co-Chairman Leaders Society

International Melanonychia Society

2008	Charter member
------	----------------

Pacific Dermatological Association

2009 – 2010	Executive committee
1994 – Present	Member

Oregon Dermatology Society Member

2006 – 2007	President
2002 – 2003	Secretary, Treasurer
1996 – 1997	Vice-President
1996 – Present	Member

Oregon Medical Association Member

Pacific Northwest Dermatological Society

1997 – Present

Women’s Dermatology Society

1989 – Present	Member
----------------	--------

Cutis Editorial Board

1998 – 2001

SkinPAC

2006 – 2008	National Chair of SkinPAC
2005 – 2006	Board of Advisors

Skin Appendage Disorders Editorial Board

2015 – Present

Publications:

Books

Rich, P, Scher RK. *An Atlas of Diseases of the Nail*. Parthenon Publisher 2003

Book Chapters

Hare, A. Q., **Rich, P.** (December 2021) Nail Physiology and Grooming. In: *Cosmetic Dermatology*. Chapter 28. Wiley.

Rich, P., Longitudinal Melanonychia. In UpToDate. 2020.

Hare A.Q., **Rich P.** (2018) Nail Cosmetics: Benefits and Pitfalls. In: Rubin A., Jellinek N., Daniel III C., Scher R. (eds) In *Scher and Daniel's Nails* (pp. 233-241). Springer, Cham.

Hare, A. Q., & **Rich, P.** (2018). Grading Onychomycosis. In *Onychomycosis: Diagnosis and Effective Management* (pp. 41-44). Wiley Blackwell.

Hare, A. Q., Bolton, E., & **Rich, P.** (2017). Non-melanocytic Melanonychia. In *Melanonychias* (pp. 97-110). Springer International Publishing.

Rich, P., & Kwak, H. S. R. (2010). Nail Physiology and Grooming. *Cosmetic Dermatology: Products and Procedures*, 197-205.

Reinig, E., **Rich, P.**, & Thompson, C. T. (2015). How to Submit a Nail Specimen. *Dermatologic clinics*, 33(2), 303-307. April 2015

Rich P, *Nail Surgery* Chapter 149 in *Dermatology* ed by **Bolognia, Jorrizzo, Rapini**. 1st Edition Mosby 2005

Rich P, *Nail Surgery* Chapter 149 in *Dermatology* ed by **Bolognia, Jorrizzo, Rapini.**, 2nd Edition Mosby 2008

Rich P Associate Editor *Nails: Diagnosis, Therapy, Surgery*. Scher, RK, 3rd Edition. Elsevier 2005

Rich P, Jefferson J. *An Approach the Patient with Abnormal Nails* in: Basow DS, ed. Waltham, MA, 2012. **UpToDate**

Jefferson J, **Rich P**, *Principle and Overview of Nail Surgery*; in **UpToDate**: Basow DS, ed. Waltham, MA, 2012

Rich P, Jefferson J. *Nail Biopsy Techniques*. in **UpToDate**: Basow DS, ed. Waltham, MA, 2012.

Jefferson J, Rich P. Chapter 38: Nail Disorders. In: Kelly P, Taylor SC, eds. *Dermatology Skin Of Color*, 2nd ed. 2013.

Rich, P, Nail Cosmetics: benefits and pitfalls. in *Nails: Diagnosis, Therapy, Surgery*, in Scher RK 3rd edition Elsevier 200

Chang RM, Hare AQ, **Rich P.** Treating cosmetically induced nail problems. *Dermatol Ther.* 2007 Jan-Feb; 20(1):54-9.

Rich P. Nail Sign and Symptoms in *Nails: Diagnosis, Therapy, Surgery*, 3rd edition, Elsevier 2005

Rich, P. Nail Cosmetics. *Dermatol Clin.* 2006 Jul;24(3):393-9. WB Saunders 2006

Rich, P., MD, Nail Disorders, Chapter in 2000 Conn's current Therapy, ed Rakel, R., W.B. Saunders, 2000.

Rich, P., Nail cosmetics and camouflaging techniques. *Dermatologic Therapy*, July/August/Sep/Oct 2001. 1-9 vol.14. Blackwell Publishing 2001

Rich, P., Nail Disorders. Diagnosis and treatment of infectious, inflammatory and neoplastic nail conditions. *Medical Clinics of North America*, Vol. 82:5 Sept 1998, Sep; 82-(5): 1171-1183.

Rich, P., Roberts, J.L., Hair, Scalp, and Nail Diseases. In Noble J. et al (editors) *Textbook of Primary Care Medicine*. 1996 Mosby Year- Book, Inc., St. Louis, MO p358-393

Publications in Peer Reviewed Journals

Blauvelt, A., **Rich, P.**, Sofen, H., Strober, B., Merola, J.F., Lebwohl, M., Morita, A., Szepietowski, J.C., Lambert, J., Hippeli, L., Colston, E., Balagula, E., Banerjee, S., Thaçi, D. Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: a subset analysis of two phase 3 randomized trials in plaque psoriasis. *J Am Acad Dermatol*. 2023 Dec 18:S0190-9622(23)03374-1. doi: 10.1016/j.jaad.2023.11.060. Epub ahead of print. PMID: 38122848.

Egeberg, A., Kristensen, L.E., Puig, L., **Rich, P.**, Smith, S.D., Garrelts, A., See, K., Holzkaemper, T., Fotiou, K., Schuster, C. Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks. *J Dermatolog Treat*. 2023 Dec;34(1):2263108. doi: 10.1080/09546634.2023.2263108. Epub 2023 Oct 2. PMID: 37781881.

Merola, J., Elewski, B., **Rich, P.**, Amin, A., Savage, L., Papp, K., Warren, R., Shah, M., Soliman, A., Shi, L., Coates, L., Impact of Risankizumab on Nail Psoriasis and Enthesitis Among Psoriatic Arthritis Patients with High Nail Symptom Burden. *JAAD*, 89(3): AB54. September 2023. DOI: 10.1016/j.jaad.2023.07.221.

Elewski, B., **Rich, P.**, Langley, R., Shah, M., Photowala, H., Wu, T., Patel, M., Crowley, J. Long-Term Improvement in Difficult-To-Treat Areas and Quality of Life in Patients with Psoriasis Up to 204 Weeks Post Switch From Ustekinumab to Risankizumab. *JAAD*, 89(3): AB190. DOI: <https://doi.org/10.1016/j.jaad.2023.07.760>.

Soung, J., Rosmarin, D., Lopez Ferrer, A., Lain, E., **Rich, P.**, White, K., Staelens, F., Szilagyi, B., Deherder, D., Magnolo, N. Bimekizumab in patients with moderate to severe plaque psoriasis: Injection site reactions through two years of the BE RADIANT phase 3b trial and open-label extension with one-year comparison to secukinumab. *JAAD*, 89(3):AB128. DOI: 10.1016/j.jaad.2023.07.515.

Feldman, S., Vlahovic, T., Joseph, W., Daniel, C. R., Elewski, B., **Rich, P.**, & Lipner, S. (2023). Monthly Usage of Efinaconazole 10% Solution in Two Phase 3 Randomized Trials: Is One 4-mL Bottle Enough for Proper Treatment?. *SKIN The Journal of Cutaneous Medicine*, 7(4), s228. <https://doi.org/10.25251/skin.7.sup.228>

Strober, B., Thaçi, D., Sofen, H., Kircik, L., Gordon, K.B., Foley, P., **Rich, P.**, Paul, C., Bagel, J., Colston, E., Throup, J., Kundu, S., Sekaran, C., Linaberry, M., Banerjee, S., Papp, K.A. Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary. *Immunotherapy*. 2023 May 7. doi: 10.2217/imt-2023-0062. Epub ahead of print. PMID: 37150956.

Tyring, S.K., **Rich, P.**, Tada, Y., Beeck, S., Messina, I., Liu, J., Huang, X., Shumack, S. Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study. *Dermatol Ther (Heidelb)*. 2023 Feb;13(2):595-608. doi: 10.1007/s13555-022-00876-x. Epub 2023 Jan 2. PMID: 36588137; PMCID: PMC9805909.

Blauvelt, A., **Rich, P.**, Sofen, H., Lambert, J., Merola, J. F., Lebwohl, M., Scharnitz, T., Hoyt, K., Kisa, R. M., & Banerjee, S. (2022). Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK

PSO-1 and PSO-2 trials. *SKIN The Journal of Cutaneous Medicine*, 6(6), s49.
<https://doi.org/10.25251/skin.6.sup.49>

Armstrong, A., McBride, S., Spelman, L., Fernandez-Penas, P., **Rich, P.**, Martin, G., Tilt, N., Lopez Pinto, J. M., Popova, C., Hellot, S. Improvements in anxiety and depression among patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from 2 phase 3 trials (CIMPASI-1 and CIMPASI-2). *Journal of the American Academy of Dermatology* (September 2022). DOI:<https://doi.org/10.1016/j.jaad.2022.06.731>.

Blauvelt, A., **Rich, P.**, Sofen, H., Lambert, J., Merola, J., Lebwohl, M., Hippeli, L., Kisa, R., Banerjee, S., & Kimball, A. (2022). Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO-1 and PSO-2 trials. *SKIN The Journal of Cutaneous Medicine*, 6(4), s41.
<https://doi.org/10.25251/skin.6.sup.41>

Gottlieb, A.B., Merola, J., Somani, N., Konicek, B., See, K., McKean-Matthews, M., Gallo, G., **Rich, P.** Ixekizumab demonstrates comprehensive psoriasis clearance in patients with moderate-to-severe psoriasis with scalp, nail, and/or palmoplantar involvement: Uncover-1, -2 trials through 5 years. *Journal of Investigative Dermatology*, August 2022. DOI: 10.1016/j.jid.2022.05.301.

Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, **Rich P**, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA, Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial, *Journal of the American Academy of Dermatology* (2022), doi: <https://doi.org/10.1016/j.jaad.2022.08.061>.

Reich, K., Kristensen, L.E., Smith, S.D., **Rich, P.**, Sapin, C., Leage, S.L., McKenzie, R., Schuster, C., Riedl, E., Gooderham, M. Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial. *Dermatol Pract Concept*. 2022 Apr 1;12(2):e2022104. doi: 10.5826/dpc.1202a104. PMID: 35646453; PMCID: PMC9116563.

Kolla, A., Starace, M., Svigos, K., Yin, L., Rich, P., Gutierre, D., Krueger, L., Adotama, P., Shapiro, J., Piraccini, B., Lo Sicco, K.. Dermatologists' knowledge of dermoscopic features in hair and nail disorders. *J Eur Acad Dermatol Venereol*. 2022 Feb 11. doi: 10.1111/jdv.18000. Epub ahead of print. PMID: 35148453.

Lipner SR, Joseph WS, Vlahovic TC, Scher RK, **Rich P**, Ghannoum M, Daniel CR, Elewski B. Therapeutic Recommendations for the Treatment of Toenail Onychomycosis in the US. *J Drugs Dermatol*. 2021 Oct 1;20(10):1076-1084. doi: 10.36849/JDD.6291. PMID: 34636509.

Lipner S, R, Ghannoum M, Hinshaw M, A, **Rich P**, Ruben B, S, Vlahovic T, C, Scher R, K: Deferring Nail Mycological Sampling during the COVID-19 Pandemic: Recommendations from a Multidisciplinary Panel of Nail Specialists. *Skin Appendage Disord* 2021. doi: 10.1159/000520628

Lipner, S., Joseph, W., Vlahovic, T., Scher, R., **Rich, P.**, Ghannoum, M., Daniel, R., & Elewski, B. (2021). Therapeutic Recommendations for the Treatment of Toenail Onychomycosis in the US. *SKIN The Journal of Cutaneous Medicine*, 5(6), s93. <https://doi.org/10.25251/skin.5.sup.93>

Lipner, S., Joseph, W., Vlahovic, T., Scher, R., **Rich, P.**, Ghannoum, M., Daniel, R., & Elewski, B. (2021). Therapeutic Recommendations for the Treatment of Toenail Onychomycosis in the US. *Journal of Drugs in Dermatology: JDD* 20(10): 1076-1084 DOI: 10.36849/JDD.6291.

Sigurgeirsson, B., Schakel, K., Chih-Ho, H., Rong, F., Hampele, I., Patekar, M., Effendy, I., Placek, W., Bruin, G., **Rich, P.**, Charef, P., Efficacy, pharmacokinetics, and tolerability of subcutaneous secukinumab injections with 2 mL prefilled syringes (300 mg) in adult subjects with moderate to severe plaque psoriasis. *JAAD Abstract only*, Volume 85, Issue 3, supplement. September 01, 2021. DOI:<https://doi.org/10.1016/j.jaad.2021.06.614>.

Baltz, J.O., Rubin, A., Adigun, C., Daniel, C.R. 3rd, Hinshaw, M., Knacksedt, T., Lipner, S.R., **Rich, P.**, Stern, D., Zaiac, M., Jellinek, N.J. Expert Consensus on Nail Procedures and Selection of CPT Codes. *Dermatol Surg.* 2021 Aug 1;47(8):1079-1082. doi: 10.1097/DSS.0000000000003081. PMID: 34397542.

Hudgens, S., **Rich, P.**, Geng, Z., Williams, D., Fleischer, A., Ganguli, A. (20 May 2021), Development and validation of the Physician's Global Assessment of Fingernail Psoriasis. <https://doi.org/10.1111/jdv.17387>

Sigurgeirsson, B., Schäkel, K., Hong, C-H., Effendy, I., Placek, W., **Rich, P.**, Keefe, D., Bruin, G., Charef, P., Fu, R., Hampele, I. & Patekar, M. (2021): Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study, *Journal of Dermatological Treatment*, DOI: 10.1080/09546634.2021.1902925

Hare, A. Q., **Rich, P.**, Nail Tumors, *Dermatologic Clinics*, Volume 39, Issue 2, 2021, Pages 281-292.

Reich, K., Conrad, C., Kristensen, L. E., Smith, S. D., Puig, L., **Rich, P.**, Sapin, C., Holzkaemper, T., Koppelhus, U. & Schuster, C. (2021): Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis, *Journal of Dermatological Treatment*, DOI:10.1080/09546634.2021.1892024.

Kaeley, G. S., Eder, L., Zehra Aydin, S., **Rich, P.**, Bakewell, C. J., Nail Psoriasis: Diagnosis, Assessment, Treatment Options, and Unmet Clinical Needs. *The Journal of Rheumatology*, Feb. 2021, jrheum.201471; DOI: 10.3899/jrheum.201471.

Hare AQ, **Rich P.** Nail Tumors. *Dermatol Clin.* 2021 Apr; 39(2):281-292. doi: 10.1016/j.det.2020.12.007. PMID: 33745640.

Reich, K., Blauvelt, A., Lebwohl M., Papp, K.A., **Rich, P.**, Strober B., De Cuyper, D., Madden, C., Peterson, L., Vanvoorden, V., Warren, R.B. Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials. Poster presented at Presented at Winter Clinical 2021 Virtual Congress | January 2021.

Reich K, Conrad C, Kristensen LE, Smith SD, Puig L, **Rich P**, Sapin C, Holzkaemper T, Koppelhus U, Schuster C. Network meta-analysis comparing the efficacy of biologic treatments

for achieving complete resolution of nail psoriasis. *J Dermatolog Treat.* 2021 Mar 1:1-9. doi: 10.1080/09546634.2021.1892024. Epub ahead of print. PMID: 33641593.

Gordon, K., Foley, P., **Rich, P.**, Duffin, K., Pinter, A., Griffiths, C., Wang, M., Vanvoorden, V., Staelens, F., Ciaravino, V., & Merola, J. (2021). Bimekizumab Versus Ustekinumab in Plaque Psoriasis: Lasting Efficacy Translates to Rapid and Sustained Improvements in Quality of Life in the BE VIVID Multicenter, Randomized, Double-Blinded Phase 3 Trial. *SKIN The Journal of Cutaneous Medicine*, 5(1), s17.

Bagel, J., Reich, K., **Rich, P.**, Bissonnette, R., Ohata, C., Papp, K., Patel, D., Zhu, B., Edson-Heredia, E., Gooderham, M., Impact of mirikizumab maintenance dosing at week 104 on health-related quality of life in patients who had less than PASI 90 response at week 16: A phase 2 study analysis, *J Am Acad Dermatol*, December 2020. Abstract.

Rich, P., Reich, K., Bissonnette, R., MD, Ohata, C., Leonardi, C., Klekotka, P., Liu, K., Patel, D., Papp, K., Consistent scalp psoriasis clearance with mirikizumab maintenance treatment at 104 weeks in patients who had less than PASI 90 response at week 16: A phase 2 study analysis, *J Am Acad Dermatol*, December 2020. Abstract.

Elewski, B., Baddley, J., Deodhar, A., Magrey, M., **Rich, P.**, Soriano, E., Soung, J., Bao, W., Patekar, M., Lebwohl, M., Sharma, A., Lack of tuberculosis reactivation in 12,319 patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis treated with secukinumab: An ad hoc analysis of pooled safety data from 28 clinical trials, *J Am Acad Dermatol*, December 2020. Abstract.

Smith, S., Kristensen, L., Schusters, C., Sapin, C., Leage, S., Riedl, E., Reich, K., **Rich, P.**, Comparison of ixekizumab and adalimumab in the treatment of nail psoriasis in psoriatic arthritis patients with moderate to severe psoriasis: 24-week results from a multicenter, randomized, open-label, rater-blinded study (SPIRIT-H2H), *J Am Acad Derm.* December 2020. Abstract.

Elewski, B., Baddley, J., Deodhar, A., Magrey, M., **Rich, P.**, Soriano, E., Soung, J., Bao, W., Keininger, D., Marfo, K., Patekar, M., Sharma, A., Shete, A., Lebwohl, M., Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis, *JAMA Dermatology*, Published Online: September 30, 2020.

Elewski, B., **Rich, P.**, Han, G., Scher, R., Efficacy of brodalumab in total clearance of nail unit psoriasis, *J Am Acad Derm.* December 2020. Abstract.

Rich, P., Goldblum, O., Disch, D., Chen-Yen, L., Merola, J., Elewski, B., Nail psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis, *J Drugs Dermatol.* 2020; 19 (8): 741-746.

Elewski, B., **Rich, P.**, Lain, E., Soung, J., Lewitt, G. M., Jacobson, A., Efficacy of Brodalumab in the Treatment of Scalp and Nail Psoriasis: Results from Three Phase 3 Trials, *J Dermatolog Treat.* 2020.

Iorizzo, M., Tosti, A., Starace, M., Baran, R., Daniel, R., Di Chiacchio, N., Goettmann, S., Grover, C., Haneke, E., Lipner, S., **Rich, P.**, Richert, B., Rigopolous, D., Rubin, A., Zaiac, M.,

Piraccini, B., Isolated Nail Lichen Planus— an expert consensus on treatment of the classical form, *JAAD*, 2020.

Blume-Peytavi, U., Fowler, J., Kemeny, L., Draelos, Z., Cook-Bolden, F., Dirschka, T., Eichenfield, L., Graeber, M., Ahmad, F., Alio Saenz, A., **Rich, P.**, Tanghetti, E. (2019) Long-term safety and efficacy of trifarotene 50 lg/g cream, a first-in-class RAR-c selective topical retinoid, in patients with moderate facial and truncal acne, *JEADV*, 2019.

Chu, A., Andre, J., **Rich, P.**, Leachman, S., Thompson, C. (2019) Immunohistochemical characterization of benign activation of junctional melanocytes and melanoma in situ of the nail unit, *J Cutan Pathol.*, 2019;1–5.

Reich K, **Rich P**, Maari C, Bissonnette R, Leonardi C, Menter A, Igarashi A, Klekotka P, Patel D, Li J, Tuttle J, Morgan-Cox M⁷, Edson-Heredia E, Friedrich S, Papp K; AMAF investigators. (2019) Efficacy and Safety of Mirikizumab (LY3074828) in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results from a Randomised Phase 2 Study. *British Journal of Dermatology*, 7 February 2019, ePublication ahead of print.

Rigopoulos, D., Baran, R., Chiheb, S., Daniel, C., Di Chiacchio, N., Gregoriou, S., Chander, G., Eckart Haneke, E., Iorizzo, M., Pasch, M., Piraccini, B., **Rich, P.**, Richert, B., Natalia Rompoti, N., Rubin, A., Singal, A., Starace, M., Tosti, A., Triantafyllopoulou, I., Zaiac, M. (2019) Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus, *Journal of the American Academy of Dermatology*. Published online 4 Feb 2019.

Jiang, B., Shang I., Kempers, S., **Rich, P.**, Marcus, S., Houlihan, A., Piacquadio, D., Pariser, D., (2019) A Randomized, Vehicle-Controlled Phase 3 Study of Aminolevulinic Acid Photodynamic Therapy for the Treatment of Actinic Keratoses on the Upper Extremities, *Dermatologic Surgery*: 11 January, 2019 – eVolume Published Ahead of Print.

Rich, P., Spellman, M., Crook, T., Vivek, P., Zang, C. (2018) Tavaborole 5% Topical Solution for the Treatment of Toenail Onychomycosis in Pediatric Patients 6 to Less Than 17 Years of Age: Results from a Phase 4 Open-Label Study. *Journal of Drugs in Dermatology*: 2019 Feb; 190.

Rich, P., Laird, M., Lo Sicco, K. (2018) Conservative Treatment of Reonychychia: A Retrospective Study of 25 Patients. *Dermatol. Surg.* Oct 19, 2018. Doi 10.1097.

Blume-Peytavi, U., Tanghetti, E., Kemeny, L., Draelos, Z., Dirschka, T., Eichenfield, L., **Rich, P.**, Graeber, M., Alio Saenz, A., Fowler, J. A Long-Term Safety and Efficacy Study of Trifarotene 50 µg/g Cream in Subjects with Facial and Truncal Acne Vulgaris. Abstract. Presented EADV September, 2018.

Moore A, Green LJ, Bruce S, Sadick N, Tschen E, Werschler P, Cook-Bolden FE, Dhawan SS, Forsha D, Gold MH, Guenther S, Kempers SE, Kircik LH, Parish JL, Rendon MI, **Rich P**, Stein-Gold L, Tying SK, Weiss RA, Nasir A, Schmitz C, Boodhoo TI, Kaoukhov A, Berk DR. Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials. *Journal Drugs Dermatol*, 2018 Sept 1;17(9): 987-996. Poster also presented at the Academy of Managed Care Pharmacy in San Diego, CA 3/27/19.

Jiang, S., Kempers, S., **Rich, P.**, Marcus, S., Piacquadio, D., Pariser, D. (2018) A Randomized, Vehicle-Controlled Phase 3 Study of Aminolevulinic Acid–Photodynamic Therapy for the Treatment of Actinic Keratoses on the Upper Extremities. *Dermatologic Surgery*, 2019 January 11.

Jiang, S., Kempers, S., **Rich, P.**, Marcus, S., Piacquadio, D., Pariser, D. (2018) A Randomized, Vehicle-Controlled Phase 3 Study of Aminolevulinic Acid–Photodynamic Therapy for the Treatment of Actinic Keratoses on the Upper Extremities. Abstract. Presented at the Fall Clinical Dermatology 2018 Congress.

Rich, P., Goldblum, O., Amato, D., Disch, D., Muram, D., Merola, J. F., Elewski, B. (2018). 395 Nail psoriasis as a predictor of skin response to ixekizumab in patients with moderate-to-severe psoriasis. Abstract. *Journal of Investigative Dermatology*, Volume 138, Issue 5, S67.

Jiang, S. B., Kempers, S., **Rich, P.**, Marcus, S., Piacquadio, D., Pariser, D. (2018). A Randomized, Vehicle-Controlled Phase 3 Study of Aminolevulinic Acid–Photodynamic Therapy for the Treatment of Actinic Keratoses on the Upper Extremities. Abstract. Summer MauiDerm NP+PA.

Rich, P., Vlahovic, T. C., Joseph, W. S., Zane, L. T., Hall, S. B., Gellings, N. L., & Adigun, C. G. (2017). Clinical trial designs for topical antifungal treatments of onychomycosis and implications on clinical practice. *Cutis*, 100(4), 259-264.

Gupta, A. K., Hall, S., Zane, L. T., Lipner, S. R., & **Rich, P.** (2017). Evaluation of the Efficacy and Safety of Tavaborole Topical Solution, 5%, in the Treatment of Onychomycosis of the Toenail in Adults: A Pooled Analysis of an 8-Week, Poststudy Follow-Up From Two Randomized Phase 3 Studies. *Journal of Dermatological Treatment*, 1-21.

Korman, N. J., Sofen, H., Fretzin, S., **Rich, P.**, Zhao, Y., Herrera, V., ... & Tying, S. (2017). Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis. *Journal of Dermatological Treatment*, 28(5), 384-389.

Elewski, B. E., **Rich, P. A.**, Behrens, F., Guillet, G., Geng, Z., & Servin, O. R. (2017). primary efficacy and safety of adalimumab in nail psoriasis from the first 26 weeks of a phase-3, randomized, placebo-controlled trial with subanalysis in patients with and without psoriatic arthritis: 5081. *Journal of the American Academy of Dermatology*, 76(6), AB204.

Elewski B, **Rich P**, Behrens F, *et al* AB0756 Primary efficacy and safety of adalimumab in nail psoriasis from the first 26 weeks of a phase-3, randomized, placebo-controlled trial with subanalysis in patients with and without psoriatic arthritis *Annals of the Rheumatic Diseases* 2017;76:1319-1320.

Elewski, B. E., **Rich, P. A.**, Okun, M. M., Papp, K., Baker, C. S., Crowley, J. J., ... & Williams, D. A. (2016, July). Adalimumab for nail psoriasis: efficacy and safety from the first 26 weeks of a Phase-3, randomized, placebo-controlled trial. In *Journal Of The European Academy Of Dermatology And Venereology* (Vol. 30, pp. 65-65). 111 River St, Hoboken 07030-5774, NJ USA: Wiley-Blackwell.

Jefferson, J., Manhart, R., Moore, J., Scher, R., & **Rich, P.** (2016). The Nail Psoriasis Severity Index (napsi) 13 years later: validation of an instrument to assess psoriatic nail involvement. *Journal of the European Academy of Dermatology & Venereology*, 30, 24.

Dennehy, E. B., Zhang, L., Amato, D., Goldblum, O., & **Rich, P.** (2016). Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3. *Journal of drugs in dermatology: JDD*, 15(8), 958-961.

Hare, A. Q., & **Rich, P.** (2016). Clinical and Educational Gaps in Diagnosis of Nail Disorders. *Dermatologic clinics*, 34(3), 269-273.

Foley, P., Rivas, E., Griffiths, C. E. M., **Rich, P.**, Notter, M., & Papavassilis, C. (2015, May). Secukinumab shows efficacy in subjects with and without previous exposure to biologic psoriasis therapy: subanalysis from the phase 3 FIXTURE study. In *AUSTRALASIAN JOURNAL OF DERMATOLOGY* (Vol. 56, pp. 36-36). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY-BLACKWELL.

Manhart, R., & **Rich, P.** (2015). Nail psoriasis. *Clin Exp Rheumatol*, 33(5 Suppl 93), 7-13.

Langley, R. G., **Rich, P.**, Menter, A., Krueger, G., Goldblum, O., Dutronc, Y., ... & Heffernan, M. P. (2015). Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. *Journal of the European Academy of Dermatology and Venereology*, 29(9), 1763-1770.

Werschler, W. P., Calkin, J. M., Laub, D. A., Mauricio, T., Narurkar, V. A., & **Rich, P.** (2015). Aesthetic Dermatologic Treatments: Consensus from the Experts. *The Journal of clinical and aesthetic dermatology*, 8(10 Suppl), S2.

Rich, P., Gooderham, M., Bachelez, H., Goncalves, J., Day, R., Chen, R., and Crowley, J. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis; results of two phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). *Submitted to JAAD July 2015*.

Pariser, D., Jellinek, N., and **Rich P.** (2015). Efficacy and Safety of Onychomycosis Treatments: An Evidence-Based Overview. *Seminars in Cutaneous Medicine and Surgery*, Supplement 3, Volume 34, NO. 3S, June 2015. pp S46-S50.

Jellinek, N., **Rich P.**, and Pariser, D. (2015). Understanding Onychomycosis Treatment: Mechanisms of Action and Formulation. *Seminars in Cutaneous Medicine and Surgery*, Supplement 3, Volume 34, NO. 3S, June 2015. pp S51-S53.

Rich P., Jellinek, N., and Pariser, D. (2015). Management Strategies for Onychomycosis in Special Patient Populations. *Seminars in Cutaneous Medicine and Surgery*, Supplement 3, Volume 34, NO. 3S, June 2015. pp S54-S55.

Young, M., Pariser, D., **Rich P.**, and Jellinek, N. (2015). Making Strides in Preventing Onychomycosis Recurrence. *Seminars in Cutaneous Medicine and Surgery*, Supplement 3, Volume 34, NO. 3S, June 2015. pp S56-S59.

Pariser, D., Jellinek, N., **Rich P.** (2015). Managing Efficacy and Safety of Onychomycosis Treatments: An Evidence-Based Overview. *Dermatology News*, June 2015. pp 5-9.

Jellinek, N., **Rich P.**, and Pariser, D. (2015). Understanding Onychomycosis Treatment: Mechanisms of Action and Formulation. *Dermatology News*, June 2015. pp 10-12.

Rich P., Jellinek, N., and Pariser, D. (2015). Management Strategies for Onychomycosis in Special Patient Populations. *Dermatology News*, June 2015. pp 13-14.

Young, M., Pariser, D., **Rich P.**, and Jellinek, N. (2015). Making Strides in Preventing Onychomycosis Recurrence. *Dermatology News*, June 2015. pp 15-18.

Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K, **Rich P** Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. *Lancet*. 2015 Aug 8;386(9993):541-51

Elewski, B. E., Aly, R., Baldwin, S. L., Soto, R. F. G., **Rich, P.**, Weisfeld, M., ... & Pollak, R. (2015). Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies. *Journal of the American Academy of Dermatology*.

Jefferson, J., Thompson, C., Hinshaw, M., & **Rich, P.** (2015). Coral contact dermatitis. *Dermatology online journal*, 21(4).

Rich, Phoebe, M.D., Efinaconazole Topical Solution, 10%: The Benefits of Treating Onychomycosis Early. *Journal of Drugs in Dermatology*, Volume 14, Issue I, January 2015, pp 611-615.

Rich, P., Bourcier, M., Sofen, H., Fakharzadeh, S., Wasfi, Y., Wang, Y., ... & Poulin, Y. (2014). Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. *British Journal of Dermatology*, 170(2), 398-407.

Hare, A. Q., Jefferson, J., & **Rich, P.** (2014). How to Choose My Treatment. In *Nail Psoriasis* (pp. 149-156). Springer International Publishing.

Stein, G. L., Kircik, L., Fowler, J., Jackson, J. M., Tan, J., Draelos, Z., ... & Jacovella, J. (2014). Long-Term Safety of Ivermectin 1% Cream vs Azelaic Acid 15% Gel in Treating Inflammatory Lesions of Rosacea: Results of Two 40-Week Controlled, Investigator-Blinded Trials. *Journal of drugs in dermatology: JDD*, 13(11), 1380-1386.

David M Pariser MD, **Phoebe Rich M.D.**, Fran E. Cook-Bolden MD, and Andrew Korotzer PhD.

An Aqueous Gel Fixed Combination of Clindamycin Phosphate 1.2% and Benzoyl Peroxide 3.75% for the Once-Daily Treatment of Moderate to Severe Acne Vulgaris. *Journal of Drugs in Dermatology*, Volume 13, Issue 9, September 2014, pp 611-617.

Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E., Papp, K., ... & Papavassilis, C. (2014). Secukinumab in plaque psoriasis—results of two phase 3 trials. *New England Journal of Medicine*, 371(4), 326-338.

Jefferson K, Thompson C, **Rich P**. A slowly enlarging mass of the finger. *Dermatol Online J*. 2014 Feb.

McInnes, I. B., Kavanaugh, A., Gottlieb, A. B., Puig, L., Rahman, P., Ritchlin, C., ... & PSUMMIT 1 Study Group. (2013). Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. *The Lancet*, 382(9894), 780-789.

Jarratt, M., Jones, T., Kempers, S., **Rich, P.**, Morton, K., Nakamura, N., & Tavakkol, A. (2013). Luliconazole for the treatment of interdigital tinea pedis: A double-blind, vehicle-controlled study. *Cutis*, 91(4), 203-210.

Chiacchio, N. D., Farias, D. C. D., Piraccini, B. M., Hirata, S. H., Richert, B., Zaiac, M., **Rich, Phoebe** ... & Tosti, A. (2013). Consensus on melanonychia nail plate dermoscopy. *Anais brasileiros de dermatologia*, 88(2), 309-313.

Pariser, D., Elewski, B., **Rich, P.**, & Scher, R. K. (2013, June). Onychomycosis information for patients. In *Seminars in cutaneous medicine and surgery* (Vol. 32, No. 2 Suppl 1, pp. 2p-following).

Rich, Phoebe, M.D., Topical Treatment of Onychomycosis With Efinaconazole Solution 10%. *CUTIS*. Volume 91, June 2013 (305-307)

Elewski, B. E., **Rich, P.**, Tosti, A., Pariser, D. M., Scher, R., Daniel, R. C., & Gupta, A. K. (2013). Onychomycosis: an overview. *Journal of drugs in dermatology: JDD*, 12(7), s96-103.

Elewski BE, **Rich P**, Pollak R, Pariser DM, Watanabe S, et. Al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. *J Am Acad Dermatol*. 2013 Apr; 68 (4):600-8

P. Rich, 1 B. Sigurgeirsson, 2 D. Thaci, 3 J.-P. Ortonne, 4 C. Paul Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. *British Association of Dermatologists* 2013 168, pp402-411

Armstrong April, Coates LC, Espinoza LR, **Rich P**. Infectious, Oncologic, and Autoimmune Comorbidities of Psoriasis and PsA: A Report from the Grappa 2012 Annual Meeting, Stockholm. *Journal of Rheumatology* In press. 2013

Elewski, B., Pollak, R., Ashton, S., **Rich, P.**, Schlessinger, J., & Tavakkol, A. (2012). A randomized, placebo-and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. *British Journal of Dermatology*, 166(2), 389-398.

Jefferson K, **Rich P.** Update on Nail Cosmetics. Dermatologic Therapy. 2012 November, 25 (6): 481-490

Jefferson, **Rich ,P** Melanonychia: Review Article in Dermatology Research and Practice. ed Haneke, Volume 2012, April 2012: 2012:1-8.

Jefferson J, Rich P. Melanonychia. Dermatology Research and Practice.

Jefferson J, **Rich P.** Expert Opinion: Onychomycosis. DermQuest.com.
http://www.dermquest.com/expert_opinions/clinical_updates/onychomycosis.html. September 19, 2011

Rich, Phoebe, M.D., Elewski, Boni, MD, Scher, Richard K, MD, Pariser, David, MD. Diagnosis, Clinical Implications, and Complications of Onychomycosis. A CME-certified supplement to seminars in Cutaneous Medicine and Surgery. Update on Onychomycosis: Effective Strategies for Diagnosis and Treatment. 1 32(2S):11-14

P Rich, M.D.; M Bourcier, MD; H Soden, MD, S Fakharzadeh, MD; Y Wasfi, MD; Y Wang, MS; U Kerkmann, PhD; P-D Ghislain, MD; Y poulin, MD Nail disease at baseline and after one year of treatment with ustekinumab in patients with moderate-to-severe psoriasis: results from PHOENIX 1. In press British J Dermatol,

Scher, Richard K, MD, **Rich, Phoebe, M.D.**, Pariser, David, MD, Elewski, Boni, MD. The Epidemiology, Etiology, and Pathophysiology of Onychomycosis. A CME-certified supplement to seminars in Cutaneous Medicine and Surgery. Update on Onychomycosis: Effective Strategies for Diagnosis and Treatment.;Supplement 1 32(2S):8-10

Elewski, Boni, MD, Pariser, David, MD, **Rich, Phoebe, M.D.**, Scher, Richard K, MD. Current and Emerging Options in the Treatment of Onychomycosis. A CME-certified supplement to seminars in Cutaneous Medicine and Surgery. Update on Onychomycosis: Effective Strategies for Diagnosis and Treatment.;Supplement 1 32(2S):15-18

Pariser, David, MD, Scher, Richard K, MD, Elewski, Boni, MD, **Rich, Phoebe, M.D.** Promoting and Maintaining or Restoring Healthy Nails: Practical Recommendations for Clinicians and Patients. A CME-certified supplement to seminars in Cutaneous Medicine and Surgery. Update on Onychomycosis: Effective Strategies for Diagnosis and Treatment.;Supplement 1 32(2S):19-20

Jefferson J, **Rich P.** Update on Nail Cosmetics. Dermatol Ther. 2012 Nov;25(6):481-90.

P. Rich,¹ B. Sigurgeirsson,² D. Thaci,³ J.-P. Ortonne,⁴ C. Paul,⁵ R.E. Schopf,⁶ A. Morita,⁷ K. Roseau,⁸ E. Harfst,⁸ A. Guettner,⁸ M. Machacek⁸ and C. Papavassilis, Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. British J dermatol. 2013 :168 pp 402-411.

Boni E. Elewski, MD, **Phoebe Rich, M.D.**, Richard Pollak, DPM, David M. Pariser, MD,

Shinichi Watanabe, MD, Hisato Senda, DVM, Chikara Ieda, PhD, Kathleen Smith, MBA,

Radhakrishnan Pilla, PhD, Tage Ramakrishna, MD, and Jason T. Olin, PhD. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2012 Nov. 22.

B.E. Elewski, M.A. Ghannoum, P. Mayser, A.K. Gupta, H.-C. Korting, R.J. Shourey, D.R. Baker, **P.A. Rich**, M. Ling, S. Hugot, B. Damaj, J. Nyirady, K. Thangavelu, M. Notter, A. Parneix-Spake, B. Sigurgeirsson. Efficacy, safety and tolerability of topical Terbinafine nail solution in patients with mid-to-moderate toenail Onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs. *Journal of the European Academy of Dermatology and Venereology* 2011

Carney C, Tosti A, Daniel R, Scher R, **Rich P**, DeCoster J, Elewski B. A new classification system for grading the severity of Onychomycosis: Onychomycosis Severity Index. PMID: 22106113

Rich, P. Are we giving nails away? *Cutis*. 2010 Jun; 85(6):280-1

Eichenfield LF, Jarratt M, Schlessinger J, Kempers S, Manna V, Hwa J, Liu Y, Graeber M; Adapalene 0.1% lotion in the treatment of acne vulgaris: results from two placebo-controlled, multicenter, randomized double-blind, clinical studies. *J Drugs Dermatol*. 2010 Jun; 9(6):639-46.

Foley P, Freeman M, Menter A, Siller G, El-Azhary RA, Gebauer K, Lowe NJ, Jarratt MT, Murrell DF, **Rich P**, Pariser DM, Oseroff AR, Barnestson R, Anderson C, Kossard S, Gibson LE, Tope WD. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. *Int J Dermatol*. 2009 NOV; 48(11):1236-45.

Guy Webster, MD, PhD, **Phoebe Rich, M.D.**, Michael Gold, MD, Serena Mraz, MD, Barry Calvarese, MS, Diana Chen, MD. Efficacy and Tolerability of a Fixed Combination of Clindamycin Phosphate (1.2%) and Low Concentration Benzoyl Peroxide (2.5%) Aqueous Gel in Moderate or Severe Acne Subpopulations. *J Drugs in Derm* 2009 Aug.

Thiboutot, Fleischer, **Rich**. Controlling Lesions and Erythema With an Azelaic Acid Gel Regimen in Rosacea (CLEAR): A Multicenter Study of Topical Azelaic Acid 15% Gel in Combination With Oral Doxycycline as Initial Therapy and Azelaic Acid 15% Gel as Maintenance Monotherapy. *J Drug in Derm* 2009 July Vol 8 pg 639.

Thiboutot DM, Fleischer AB, Del Rosso JQ, **Rich P**. A multicenter study of topical Azelaic acid 15% gel in combination with oral Doxycycline as initial therapy and Azelaic acid 15% gel as maintenance Monotherapy. PMID: 19588640.

Rich P, Griffiths CE, Reich K, Nestle FO, Scher RK, Li S, Xu S, Hsu MC, Guzzo C. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. *J Am Acad Dermatol*. 2008 Feb; 58 (2):224-31.

Rich, P. Hormonal Contraceptives for Acne Management. *Cutis* vol 81, Jan 2008 pp13-18.

Thiboutot DM, Harper JC, O'Connell K, **Rich P**, Sondheim SJ. Improving acne outcomes through collaboration. *Cutis* 2008 Jan; 81(1 suppl):26-31.

Rich P, Griffiths CE, Reich K, Nestle FO, Scher RK, Li S, Xu S, Hsu MC, Guzzo C. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. *J Am Acad Dermatol*. 2007 Dec 20.

Del Rosso JQ, Webster GF, Jackson M, Rendon M, **Rich P**, Torok H, Bradshaw M. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline mg

doxycycline, USP capsules) administered once daily for treatment of rosacea. *J Am Acad Dermatol.* 2007 May;56(5):791-802. Epub2007 Mar 23.

Del Rosso JQ, Draelos ZD, Jorizzo JL, Joseph WS, Ribotsky BM, **Rich P.** Modern methods to treat superficial fungal disease. *Cutis.* 2007 Feb;79(2 Suppl):6-29.

Hare AQ, **Rich P.** Treating cosmetically induced nail problems. *Dermatol Ther.* 2007 Jan-Feb;20(1):54-9. Review.

Cassell SE, Bieber JD, **Rich P,** Tutuncu ZN, Lee SJ, Kalunian KC, Wu CW, Kavanaugh A. The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriasis nail involvement in patient with psoriatic arthritis. *J Rheumatol.* 2007 Jan; 34(1):123-9

Sigurgeirsson B, Elewski BE, **Rich PA,** Oppen C, Cai B, Nyirady J, Bakshi R. Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: a randomized, double-blind comparison. *J Dermatolog Treat.* 2006; 17(1):38-44

Rich, P. Nail Cosmetics. *Dermatol Clin.* 2006 Jul;24(3):393-9. Review

Rich, P. Treatment of uncomplicated skin and skin structure infections in the diabetic patient. *J Drugs Dermatol.* 2005 Nov-Dec; 4(6Suppl): s 26-9. Review

Torok HM, Jones T, **Rich P,** Smith S, Tschen E. Hydroquinone 4% tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for Melasma. *Cutis.* 2005 Jan;75(1):57-62.

DiGiovanna JJ, Langman CB, Tschen EH, Jones T, Menter A, Lowe NJ, Eichenfield L, Herbert AA, Pariser D, Savin RP, Smith SR, Jarratt M, Rodriguez D, Chalker DK, Kempers S, Ling M, Rafal ES, Sullivan S, Kang S, Shah LP, Wu E, Newhouse J, Pak J, Eberhardt DR, Bryce GF, McLane JA, Ondovik M, Chin C, Khoo KC, **Rich P.** Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne. *J Am Acad Dermatol.* 2004 Nov;51(5):709-17.

Rich, P. Scher, RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. *J Am Acad Dermatol.* 2003 Aug;49(2):206-12.

Rich P, Harkless LB, Atillasoy ES. Dermatophyte test medium culture for evaluating toenail infections in patients with diabetes. PMID: 12716808.

John K. Geisse, **Phoebe Rich,** Amit Pandya, Kenneth Gross, Kara Andres, Angie Ginkel, Mary Owens. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. *Journal of the American Academy of Dermatology.* 2002 Sep;47(3):390-8.

Taylor S, MD, Torok H, MD, Jones T, MD, Lowe N, MD, **Rich, P MD,** Tschen E, MD, Menter A, MD, Baumann L, MD, Wieder J, MD, Jarratt M, MD, Pariser D, MD, Martin D, MD, Weiss J, MD, Shavin J,

MD, Ramirez N, MD. Efficacy and Safety of a New Triple combination Agent for the Treatment of Facial Melasma. *Cutis.* 2003 Jul;72(1):67-72.

Diane Thiboutot, MD, Michael Jarratt, MD, **Phoebe Rich, M.D.**, Toivo Rist, MD, David Rodriguez, MD, and Sharon Levy, MD. A Randomized Study comparing the Efficacy and Safety of a Novel

Rich, P. (2002). Nail changes due to diabetes and other endocrinopathies. *Dermatologic Therapy*, 15(2), 107-110.

Erythromycin/Benzoyl Peroxide Gel System with an Available Erythromycin/Benzoyl Peroxide Preparation or Vehicle control for Acne Vulgaris. Clinical Therapeutics May 2002.

Jarratt, M., **Rich, P.**, Rist, T., Thiboutot, D., Rodriguez, D. Erythromycin/Benzoyl Peroxide Pak: Comparable Efficacy to the Currently Marketed Product for the Treatment of Acne Vulgaris. Abstract. AAD 2002 Annual Meeting.

Rich P, Harkless, LB, Atillysoy ES. Dermatophyte test medium culture for evaluating toenail infections in patients with diabetes. Diabetes Care. 2003 May; 26(5):1480-4.

Rich, P., Nail cosmetics and camouflaging techniques. *Dermatologic Therapy*, July/August/Sep/Oct 2001. 1-9 vol. 14

Smith S, Houpt K, **Rich, P.**, LaMarca A, Weinberg JM, Alfrerez TS, Atillasory E, Oppen C. Short- duration oral terbinafine for the treatment of tinea pedis in HIV-positive patients. *Cutis*, 2001 Jul; 68(1Suppl):30-9.

Rich, P., Houpt KR, LaMarca A, Loven KH, Marbury TC, Matheson R, Miller B, Smith S, Wofe J. Safety and efficacy of short-duration oral terbinafine for the treatment of tinea corporis or tinea cruris in subjects with HIV infection or diabetes. *Cutis*. 2001 Jul; 68-(1Suppl):15-22.

John K. Geisse, **Phoebe Rich**, Amit Pandya, Kenneth Gross, Kara Andres, Angie Ginkel, Mary Owens. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. Poster and abstract presented at the 8th World congress on Cancers of the Skin, Zurich, Switzerland, July 18-21-2001.

Goldman, BD, **Rich, P.** Subungual melanoma obscured by nail polish. *J Am Acad Dermatol*. 2001 May; 44(5):875.

Rich, P., MD, Nail Biopsy: Indication and Methods. *Dermatologic Surgery* Volume 27 Number 3 March 2001 pp229-234.

Rich P. Onychomycosis and tinea pedis in patients with diabetes. *J Am Acad Dermatol*. 2000 Nov;43(5 Suppl):S130-4. Review.

Rich, P., MD, Nail Disorders, Chapter in 2000 Conn's current Therapy, ed Rakel, R., W.B. Saunders, 2000. M.A. Ghammoum, PhD, R. Hajjeh, MD, R. Scher, MD, N. Konnikov, MD, A. Gupta, MD, R. Summerbell, PhD, S. Sullivan, MD, R. Daniel, MD, P. Krusinski, MD, P. Fleckman, MD, **P. Rich, MD**, R. Odom, MD, R.f Aly, MD, D. Pariser, MD, M. Zaiac, MD, J. Leshner, MD, B. Gerlach, MD, R.G. Ponce-de-Leon, A. Ghannoum, J. Warner, BA, N. Isham, BA, M(ASCP), B. Elewski, MD.,: A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. *J Am Acad Dermatol*, 2000 Oct;43(4):641-8.

Lawry, M., **Rich, P.**, The Nail Apparatus: A Guide for Basic and Clinical Science., Mosby September-October 1999, Volume 11 Number 5p 167-208.

Rich, P., Hare, A., Onychomycosis In A Special Patient Population: Focus On The Diabetic, Int J Dermatol, 1999, Sep 38, Suppl 2: 17-19.

Rich, P., Nail Cosmetics and Esthetics. Skin Pharmacology and Applied Skin Physiology, Vol 12:3, May-June 1999, pp 144-145.

Gupta AK, Donnikov N. MacDoncald P, **Rich, P.**, Rodger NW, Edmonds MW, McManus R, Sumkmerbell RC. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol. 1998 Oct; 139(4):665-71.

Gupta, AK, Scher, RK, **Rich, P.**, Fluconazole for the treatment of onychomycosis: an update, International Journal of Dermatology, 1998 Nov; 37 (11):815-20. .

Rich, P., Nail Disorders. Diagnosis and treatment of infectious, inflammatory and neoplastic nail conditions. Medical Clinics of North America, Vol. 82:5 Sept 1998, Sep; 82-(5): 1171-1183.

Rich, P., Schein, J., Lubeck, D. Onychomycosis: Symptoms and Quality of Life Associated With This Medical Condition. Publication.

Rich, P., Scher, R., et al Pharmacokinetics of Three Doses of Once-Weekly Fluconazole (150mg, 300mg, 450mg) in the Treatment of Distal Subungal Onychomycosis of the Toenail. J Am Acad Dermatol 1998 Jun; 38(6 Pt 2):S110-6

Savin, R., **Rich, P.**, et al Pharmacokinetics of Three Once-Weekly Fluconazole (150mg, 300mg, 450mg) in the Treatment of Distal Subungal Onychomycosis of the Fingernail. J Am Acad Dermatol 1998 June; 38(6 Pt 2):S103—9.

Drake, L., **Rich, P.**, et al A Placebo-Controlled, Randomized, Double-Blind Trial of Once-Weekly Fluconazole (150mg, 300mg, 450mg) in the Treatment of Distal Subungal Onychomycosis of the Fingernail. J Am Acad Dermatol. 1998 Jun;38(6 Pt 2);S87-94.

Scher, R., **Rich, P.**, et al A Placebo-Controlled, Randomized, Double-Blind Trial of Once-Weekly Fluconazole (150mg, 300mg, 450mg) in the Treatment of Distal Subungal Onychomycosis of the Toenail. J. Am Acad Dermatol. 1998 Jun; 38(6 Pt 2):S 77-86.

Rich, P., Roberts, J.L., Hair, Scalp, and Nail Diseases. In Noble J. et al (editors) Textbook of Primary Care Medicine. 1996 Mosby Year- Book, Inc., St. Louis, MO p358-393

Rich, P. Special patient populations: Onychomycosis in the Diabetic Patient. Journal American Academy of Dermatology 1996; Sep: 35 (3 Pt2) S: 3:10-12.

Rich, P. Nail Biopsy: Indications and Methods. Journal Dermatologic Surgery and Oncology. 1992 Aug; 18(8): 673-82.

Jetmalani-SN, **Rich, P.**, White, CR. Painful Solitary Subungal Nodule. Painful solitary subungal Exostosis (SE). Arch. Dermatol. 1992 Jun; 128(6):849, 852.

Rich, P., Belozer, M.L., Norris, P., Storrs, F.J., Allergic Contact Dermatitis to Two Antioxidants in Latex Gloves: 4,4'-thiobis(6-tert-butyl-meta-cresol)(Lowinox 44S36) and

butylhydroxyanisole. Allergen Alternatives for Glove-Allergic Patients. J Am Acad Dermatol 1991 Jan (1);37-43.

Rich, P., Berger, C., White, C.R., Herpes Simplex and Herpes Zoster. Chapter in Conn's Therapy, ed Rakel, R., W.B. Saunders, 1989

Hare, J.F. Huston, M., **Rich, P.**, Differential Turnover of Exogenous Membrane Polypeptides Implanted into the Hepatoma Membrane Federal Proceedings 1983; 7B:378.

Robertson, M.H., **Rich, P.**, Parker, F., Hannifin, J.M., Ketoconazole in Griseofulvin Resistant Dermatophytosis. J Am Acad Dermatol 1982 Feb; 6(2):224-9.

Posters

Elewski, B., **Rich, P.**, Crowley, J., Foley, P., Zhan, T., Zhao, Y., Rubant, S., Poulin, Y. Efficacy and Safety of Long-Term Risankizumab Treatment for Nail, Scalp, and Palmoplantar Psoriasis: An Interim Analysis From the Open-Label Extension LIMMitless Trial. Presented at: ACDCD Colombian Congress 2022.

Blauvelt, A., **Rich, P.**, Sofen, H., Lambert, J., Merola, J., Lebwohl, M., Hippeli, L., Kisa, R., Banerjee, S., Kimball, A., Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO-1 and PSO-2 trials. Presented at: San Diego Dermatology Symposium (SDDS); March 11-13, 2022 in San Diego, CA.

Rich P, et al. Improvement in Psoriasis Scalp Severity Index during maintenance treatment with mirikizumab. Patients maintain scalp psoriasis clearance with higher doses of mirikizumab. Presented at: 24th World Congress of Dermatology; June 10-15, 2019; Milan, by Dr. Phoebe Rich.

Moore A, Green LJ, Bruce S, Sadick N, Tschen E, Werschler P, Cook-Bolden FE, Dhawan SS, Forsha D, Gold MH, Guenther S, Kempers SE, Kircik LH, Parish JL, Rendon MI, **Rich P**, Stein-Gold L, Tying SK, Weiss RA, Nasir A, Schmitz C, Boodhoo TI, Kaoukhov A, Berk DR. Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials. Poster presented at the Academy of Managed Care Pharmacy in San Diego, CA 3/27/19.

Rich, P., Baker, C., Valenzuela, F., Rey, M., Geng, Z., Gu, Y., Reyes Servin, O., Poulin., Y. (2018) Efficacy of Adalimumab in Nail Psoriasis by Baseline Subgroups, and Overall Safety from First 26 Weeks of a Phase-3, Randomized, Placebo-Controlled Trial. Presented at the 2019 Annual American Academy of Dermatology Meeting, February 2019.

Blauvelt, A., Armstrong, A., **Rich, P.**, Kisa, R., Guana, A., Meng, X., Callis Duffin, K. (2018) Secukinumab Provides Complete or Almost-complete Psoriasis Clearance in Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of 4 Phase 3 Trials. Poster presented at: 36th Annual Fall Clinical Dermatology Conference, Las Vegas, NV, USA; October 12–15, 2017. Poster presented at: 13th Annual Winter Clinical Dermatology Conference, Maui, HI, USA; January 12–17, 2018.

Dermatologie, C. H. U., & Alger, A. (2016). Oral and Poster Communications.

J Jefferson, R Manhart, J Moore, R Scher, **P Rich**. The Nail Psoriasis Severity Index (NAPSI): Validation of an Instrument to Assess Psoriatic Nail Involvement. Presented at: Psoriasis, 5th Congress of the Psoriasis International Network; 2016 July 7-9, 2016; Paris France.

B Elewski, **P Rich**, M Okun, K Papp, C Baker, J Crowley, G Guillet, Y Gu, Z Geng, M Sundaram, D Williams. Adalimumab for Nail Psoriasis: Efficacy and Safety from the First 26 Weeks of a Phase-3, Randomized, Placebo-Controlled Trial. Presented at: Psoriasis, 5th Congress of the Psoriasis International Network; 2016 July 7-9, 2016; Paris France.

Jefferson J, Manhart R, Moore J, Scher R, **Rich P**. The NAPSI 12 years later: Validation of a nail psoriasis assessment tool and a review of its use and controversy. GRAPPA 2015 Annual Meeting

and Trainee Symposium. Stockholm, Sweden. Jul., 2015; 2015 Johns Hopkins Research Day. Baltimore, MD. Apr., 2015.

Foley, P., Papp, K., Reich, K., Leonardi, C., Kircik, L., Chimenti, S., **Rich, P.**,... & Griffiths, C. E. M. (2014, May). Apremilast, an oral phosphodiesterase 4 inhibitor, in nail and scalp psoriasis: 52-week results from the ESTEEM 1 study. In *AUSTRALASIAN JOURNAL OF DERMATOLOGY* (Vol. 55, pp. 34-35). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY-BLACKWELL.

R Bissonnette, J Cather, **P Rich**, A Menter, C Ferrandiz, M Goodfield, C Hu, R Day, M Sebastian. Efficacy of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Palmoplantar Psoriasis in Patient With Moderate to Severe Plaque Psoriasis in Phase 2 and Phase 3 (ESTEEM) Trials. Presented at: 11th Annual Coastal Dermatology Symposium; September 22-26, 2015; Napa CA. 2015 Fall Clinical Dermatology Conference (FCD) 2015; October 2015; Washington DC. Skin Disease Education Foundation's 16th Annual Las Vegas Dermatology Seminar & the 12th Annual SDEF Psoriasis Forum; November 5-7 2015; Las Vegas NV. Society of Dermatology Physician Assistants (SDPA) Fall 2015 Congress; November 12-15, 2015; Orlando Florida.

M Lebwohl, A Gottlieb, B Elewski, **P Rich**, S Jazayeri, K Reich, J Nyirady, Y Zhao, MH Tran, L McLeod, M Mordin, L Nelson, B Strober. Secukinumab Impact on Patient-Reported Psoriasis Experiences: Analysis of the Psoriasis Symptom Diary from the ERASURE and FIXTURE Trials. Presented at AAD 2015 in San Francisco CA, March 19-24, 2015.

J Szepietowski, **P Rich**, J Loeffler, C Papavassilis, T Fox. Secukinumab shows efficacy in subjects with and without previous exposure to biologic psoriasis therapy: subanalysis from the phase 3 FIXTURE study. Presented at the MauiDerm Conference in Maui, HI, January 26-30, 2015.

J Szepietowski, **P Rich**, J Loeffler, C Papavassilis, T Fox. Secukinumab shows efficacy in subjects with and without previous exposure to biologic psoriasis therapy: subanalysis from the phase 3 FIXTURE study. Presented at the Winter Clinical Dermatology Conference in Lahaina, HI, January 16-21, 2015.

Elewski BE, **Rich P**, Wiltz H, Aly R, Baldwin SL, Zane LT, Gonzalez Soto R. Effectiveness and Safety of Tavaborole, a Novel Boron-Based Molecule for the Treatment of Onychomycosis: Results from Two Phase 3 Trial Studies.

P. Rich, K. Kingo, E. Marmur, A. Karpv, C. Papavassilis. Secukinumab Efficacy Stratified by Body Weight: A Subanalysis From the Erasure Phase 3 Study in Psoriasis. ERASURE Study Group.

P Rich, R. G. Langley, A. Menter, G. Kreuger, B. Zhu, H. Wei, G.S. Cameron, M.P. Heffernan. Improvement in nail psoriasis in the open-label extension of a phase-2 trial of ixekizumab in patients with moderate-to-severe plaque psoriasis. Australian Congress of Dermatology.

Jefferson J, **Rich P**. Nail Psoriasis and Potential Comorbidities. 4th Annual Resident, Postdoc, and Fellow Research Day. University of Kansas Medical Center, Kansas City, KS. May, 2013.

Jefferson J, **Rich P**. Nail Psoriasis and Potential Comorbidities. GRAPPA 2012 Annual Meeting and Trainee Symposium. Stockholm, Sweden. June 2012.

PA Rich, B Sigurgeirsson, A Guettner, M Machacek, C Papavassilis³: A2211 abstract (Repurpose of AAD 2012 abstract) Efficacy and safety of Secukinumab (a fully human anti-Interleukin-17A antibody) in a phase II regimen-finding study for the treatment of moderate-to-severe plaque psoriasis. World Psoriasis and Psoriatic Arthritis congress. WPPAC 2012, Stockholm, 2012.

PA Rich, B Sigurgeirsson, A Guettner, M Machacek, C Papavassilis³ WPPAC 2012: A2211 abstract (Rep AAD 2012 abstract) Efficacy and safety of Secukinumab (a fully human anti-Interleukin-17A antibody) in a phase II regimen-finding study for the treatment of moderate-to-severe plaque psoriasis Poster AAD 2012, San Diego

K. Papp, **P. Rich**, A. Hu, R.M. Day. Apremilast Is Effective in the Treatment of Nail Psoriasis: Results From a Phase 2b, Randomized, Controlled Study. Poster AAD 2012 meeting. San Diego

P. Rich, R. Langley, C. Guzzo, Y. Wang, L. Rosoph, K. Gordon. Improvement in Nail Psoriasis with Ustekinumab, a New Anti-IL-12/23p40 Monoclonal Antibody: Results from a Phase 3 Trial. Poster. Summer AAD 2008 meeting.

P. Rich, C. Guzzo, S. Li, K. Reich. Nail Psoriasis Improvement is Maintained in Patients with Moderate-to-Severe Psoriasis Treated with Infliximab. Poster. World Congress Dermatology Buenos Aires. 2007.

P. Rich. Efficacy and Safety of Efalizumab for Nail Psoriasis: Results of an Open-Label, Multicenter Study. Poster. AAD 2006

P. Rich, C. Guzzo, S. Li, K. Reich. Nail Psoriasis Improvement is Maintained in Patients with Moderate-to-Severe Psoriasis Treated with Infliximab. Poster. European Academy of Dermatology and Venereology. Rhodes, Greece 2007

S. Bruce, **P. Rich**, D. Berson, D. Horne, A. Houlihan, M. Ferdon. A Phase II, Randomized, Investigator Blinded, Parallel Group Study of Photodynamic Therapy (PDT) With Topical 20% Aminolevulinic Acid HCL (ALA) and Visible Blue Light vs. Vehicle (VEH) and Visible Blue Light in the Treatment of Moderate to Severe Acne Using Various Drug Incubation Times. Poster. Summer AAD meeting 2007

P. Rich. Topical Antifungal Treatment for Immunocompromised Patients. Poster. Summer AAD 2007.

P. Rich, A. Gupta, A. Wang, A. Jahreis. Etanercept Improves nail Psoriasis. Poster. AAD Summer meeting 2005.

P. Rich, A. Gupta, A. Wang, A. Jahreis. Etanercept Improves nail Psoriasis. Poster. AAD Annual meeting 2005.

P. Rich, E.H. Tschen, T. Jones, A. Menter, N.J. Lowe, L. Eichenfield, A.A. Herbert, D. Pariser, R.P. Savin, S.R. Smith, M. Jarratt, D. Rodriguez, D.K. Chalker, S. Kempers, M. Ling, E.S. Rafal, S. Sullivan, J.J. DiGiovanna, S. Kang, K-C.Khoo. Effect of a Single Course of Isotretinoin therapy on Bone Mineral Density (BMD) in Pediatric Patients with Severe, Recalcitrant, Nodular Acne. Poster. July 2002 AAD meeting.

Taylor S, MD, Jones T, MD, PA, Lowe N, MD, Baumann L, MD, Jarratt M, MD, Martin D, MD, Menter A, MD, Pariser D. MD, **Rich, P.**, Ramirez N, MD, Shavin J, MD, Tschen E, MD, Weiss J, MD, Wieder J, MD. Efficacy and Safety of a Triple Combination Agent For The Treatment of Facial Melasma. Poster. February 2002 AAD meeting.

Konnikov, N., Drake, L., Stewart, M., **Rich, P.** A Placebo-Controlled, Randomized, Double-Blind Trial of Once-Weekly Fluconazole (150, 300, or 450mg) in the Treatment of Distal Subungual Onychomycosis of the Fingernail. Poster. 56th Annual AAD meeting.

Scher, R., Breneman, D., **Rich, P.**, Savin, R. Pharmacokinetics and Efficacy of Once-Weekly Fluconazole (150, 300, or 450mg) in Distal Subungual Onychomycosis of the Toenail. Poster. 56th Annual AAD meeting, 1998.

Rich, P. Patient Acceptance of Intermittent or “Pulse” Itraconazole Treatment of Toenail Onychomycosis. Poster. 55th Annual AAD meeting, 1997.

Rich, P., Karchmer, A. The Safety and Efficacy of Oral Terbinafine in the Treatment of Onychomycosis in Diabetic Patients. Poster. March 2000 AAD meeting.

Phoebe Rich, M.D., Bernie Severson, MA. Nail Terminology Made Easy. Poster. March 2001 AAD meeting. Atillasoy, E.,

Rich P, Atillistoy E, Karchmer, Onychomycosis in the Diabetic patient. Quality of life. EADV 1999

Thiboutot, D., Jarratt, M., **Rich, P.**, Rist, T. Treatment with a Novel Combination Erythromycin Benzoyl Peroxide Gel System Significantly Improves the Signs of Acne Vulgaris. Poster. March 2001 AAD meeting.

Rich, P., Geisse, J., Sterry, W., Marks, R. Imiquimod 5% With and Without Occlusion for the Treatment of Patients with Superficial BCC. Poster. February 2002 60th Annual AAD meeting.

Allevato, M., Scher, R., Rosso, J., **Rich, P.** The Nail: Common and Uncommon Cases. Check your Knowledge. Part II: Tumoral Diseases. Poster. February 2002 AAD 60th Annual meeting.

Jarratt, M., **Rich, P.**, Rist, T., Thiboutot, D. Erythromycin/Benzoyl Peroxide Pak: Comparable Efficacy to the Currently Marketed Product for the Treatment of Acne Vulgaris. Poster, Abstract. February 2002 AAD 60th Annual meeting.

Gupta, A., **Rich, P.** The Use of Terbinafine to Treat Onychomycosis in Special Populations. Poster. August 1998 AAD meeting.

Rich, P. The Efficacy and Tolerability of Intraconazole Compared with Fluconazole in the Treatment of HIV Patients. Poster. August 1998 AAD meeting

Rich, P., Schein, J., Lubeck, D. Onychomycosis: Symptoms and Quality of Life Associated with this Medical Conditions. Poster. August 1998 AAD meeting.

Rich, P., Patient Acceptance of Intermittent or Pulse Itraconazole Treatment of Toenail Onychomycosis. Poster and abstract presented at the 19th World Congress of Dermatology, Sydney, Australia, June 15-20, 1997.

Clinical Research:

- 2024 A Clinical Trial to Evaluate the Efficacy and Safety of trade name in Adults Subjects with Atopic Dermatitis and Moderate-to-Severe Atopic Hand Eczema who are Candidates for Systemic Therapy
- 2024 A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy, Safety, and Tolerability of Investigational Product in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy
- 2023 A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of trade name for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment
- 2023 A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of trade name on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis
- 2023 Randomized Double-Blind Vehicle-Controlled Study of the Safety and Efficacy of trade name in Subjects with Seborrheic Keratosis
- 2023 A Phase 4 Multicenter, Randomized, Double-Blind Study of trade name for the Treatment of Adult Subjects with Moderate to Severe Genital Psoriasis or Moderate to Severe Scalp Psoriasis
- 2023 A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of trade name for the Treatment of Participants with Plaque Psoriasis involving Special Areas
- 2023 A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Trade Name in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis
- 2023 A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Trade Name Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema
- 2023 A Randomized, Double-Blind, Vehicle Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of trade name in Male Subjects with Androgenetic Alopecia
- 2023 A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of trade name in adult and adolescent subject with severe alopecia areata
- 2023 A phase 3b, interventional, clinical trial to evaluate the efficacy and safety of Trade Name 300 mg every second week monotherapy compared with placebo in subjects with Moderate-to-severe atopic hand eczema who are candidates for systemic therapy.
- 2023 An Open Label Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability and

Pharmacokinetics of Hallux Trade Name Subungual Topical Gel 42% Administered onto the Nail Bed of Patients with Distal-Lateral Subungual Onychomycosis

- 2023 A Phase 3b/4 Randomized, Open-label, Efficacy Assessor Blinded Study, Comparing the Safety and Assessor Blinded Efficacy of Trade Name to Trade Name in Subjects with Moderate to Severe Atopic Dermatitis
- 2023 An Open-Label, Single-Arm, Phase 4 Study of Trade Name Cream in Adults with Atopic Dermatitis Experiencing Sleep Disturbance in the United States
- 2022-2023 A Phase 2b Multicenter, Long-Term Extension, Dose-ranging Study to Evaluate the Efficacy and Safety of Trade Name for the Treatment of Moderate-to-Severe Plaque Psoriasis
- 2022 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Trade Name in Adult Subjects with Moderate-to-Severe Atopic Dermatitis Inadequately Controlled by Topical Treatments
- 2022 A Multi-center, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical trade name in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)
- 2022 A Phase 2b Multicenter, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Trade Name for the Treatment of Moderate-to-Severe Plaque Psoriasis
- 2022-2024 A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Trade Name in Adult Patients with Moderate-to-Severe Atopic Dermatitis
- 2022 A Phase 2 Dose-finding Study to Evaluate the Efficacy, Safety and Immunogenicity of Trade Name in Subjects with Moderate to Severe Hidradenitis Suppurativa
- 2022 An Observer-Blinded, Randomized, Aqueous Gel Controlled Trial of the Safety and Efficacy of Trade Name Gel, Trade Name Gel, and Aqueous Gel in Subjects with Interdigital Tinea Pedis
- 2022 An open-label, single-arm, phase 3 trial to evaluate the safe and effective use of an auto-injector for administration of trade name in subjects with moderate-to-severe atopic dermatitis
- 2022-2023 A Dose-Ranging Study of the Efficacy and Safety of Trade Name in Participants with Moderate-to-Severe Plaque Psoriasis
- 2021 A Phase 4 Multicenter, Randomized, Open-Label, Efficacy Assessor-blinded Study of Trade Name Compared to Trade Name for the Treatment of Adult Subjects with Moderate Plaque Psoriasis who are Candidates for Systemic Therapy
- 2021 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of Trade Name in Subjects with Psoriasis

2021	A Multicenter, Randomized, Double-blind Study Evaluating Pharmacokinetics, Efficacy, and Safety of Multiple Switches Between Trade Name and Trade Name Compared with Continued use of Trade Name in Subjects with Moderate to Severe Plaque Psoriasis
2021	A phase 2a, multicenter, double blind, placebo controlled, randomized clinical trial to assess safety, efficacy and pharmacokinetics of trade name delayed-release in patients with moderate-to-severe papulopustular rosacea
2021	A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Trade Name Cream Followed by a Long-Term Safety Extension Period in Children (Ages > 2 Years to <12 Years) with Atopic Dermatitis
2021-2022	A Phase 3 Study of Trade Name for the Treatment of Plaque Psoriasis in Pediatric Subjects
2021	A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of trade name Cream 0.15% and trade name Cream 0.05% in Subjects with Atopic Dermatitis
2021-2023	A Phase 3 Efficacy and Safety Study of trade name for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults
2021-2023	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of trade name in Subjects with Non-Segmental Vitiligo
2021-2023	A randomized, double-blind, multicentric, parallel group therapeutic equivalence study comparing efficacy, safety, and immunogenicity of subcutaneous Trade Name and EU sourced Trade Name in patients with moderate to severe chronic plaque psoriasis.
2021	A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of Trade Name Cream 0.15% and Trade Name Cream 0.05% in Subjects with Atopic Dermatitis
2021-2023	A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of Trade Name Cream 0.05% Administered QD in Subjects with Atopic Dermatitis
2021-2022	A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Efficacy and Safety of Trade Name Compared with Trade Name in Subjects with Moderate to Severe Plaque Psoriasis
2020-2021	Phase 3 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy, Safety and Tolerability of Trade Name Vehicle Gel Once Daily in the Treatment of Molluscum contagiosum
2020	A Phase 2, Multicenter, Open-Label Study of the Long-Term Safety of Trade Name Foam 0.3% in Subjects with Seborrheic Dermatitis
2020-2021	A Phase 1/2b, Multiple Dose and 12-Week, Parallel Group, Double Blind, Dose Ranging, Vehicle-Controlled Study of the Safety and Efficacy of Trade Name Cream 0.1% and Trade Name Cream 0.3% in Subjects with Chronic Hand Eczema

2020	A double-blind, multicenter, long-term follow-up study to assess recurrence of Actinic Keratosis in subjects treated with Trade Name or vehicle cream in the treatment of thin and moderately thick, nonhyperkeratotic, non-pigmented actinic keratosis of the face and scalp when using daylight photodynamic therapy (DL-PDT), for subjects achieving complete response of treated lesions at Final Visit in Study RD.06.SPR.112199
2020	A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Trade Name in Subjects with Moderate-to-Severe Atopic Dermatitis
2020	A Long-Term Study To Assess The Safety And Efficacy Of Trade Name In Patients With Moderate-To-Severe Atopic Dermatitis
2020	A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy And Safety Of Trade Name When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-to-Severe Atopic Dermatitis
2020-2020	A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of Trade Name Foam 0.3% Administered QD in Adolescents and Adults with Scalp and Body Psoriasis
2020-2020	A Phase 2a, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of Trade Name Foam 0.3% Administered QD in Subjects with Seborrheic Dermatitis
2020-2021	A Double-Blind, Randomized, Placebo-Controlled Study To Assess The Efficacy And Safety Trade Name In The Treatment Of Subjects With Moderate To Severe Palmar Hyperhidrosis
2019-2020	A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied Trade Name Gel, 15% in Subjects with Axillary Hyperhidrosis (the “Cardigan I Study”)
2019-2020	A Multicenter, Randomized, Double-Blinded, Placebo-Controlled 16-Week Study (with a 52-Week Open-Label Extension) to Assess the Safety and Efficacy of Trade Name in Subjects with Moderate-to-Severe Atopic Dermatitis
2019	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Trade Name in Adult Patients with Severe or Very Severe Alopecia Areata
2019-2021	A Long-Term, Open Label, Extension Study to Evaluate the Safety and Efficacy of Trade Name, 1% for the Treatment of Plaque Psoriasis in Adults
2019	A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Trade Name cream versus vehicle cream in the treatment of thin and moderately thick, non-hyperkeratotic, non-pigmented actinic keratosis of the face and scalp when using daylight photodynamic therapy
2019	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Trade Name in Subjects with Moderate-to-Severe Atopic Dermatitis

2019	An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of Trade Name in Subjects with Moderate-to-Severe Plaque Psoriasis
2019	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy and Safety of Trade Name in the Treatment of Moderate to Severe Nail Psoriasis
2019-2020	A Phase 3 Efficacy and Safety Study of Trade Name for the Treatment of Plaque Psoriasis in Adults
2019-2020	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety in Adult Subjects with Moderate-to-Severe Atopic Dermatitis
2018-2020	A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate trade name in Adult and Adolescent Subjects with Moderate to Severe Atopic Dermatitis
2018-2022	An open-label, single-arm, multi-centre, long-term extension trial to evaluate the safety and efficacy of trade name in subjects with atopic dermatitis who participated in previous trade name clinical trials
2018-2020	Multicenter, randomized, double-blind, placebo-controlled, 52 week study to demonstrate the efficacy, safety and tolerability of subcutaneous trade name injections with 2 mL auto-injectors (300 mg) in adult subjects with moderate to severe plaque psoriasis-MATURE
2018	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Trade Name to Trade Name and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis
2018	A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Trade Name in Adult Patients with Moderate to Severe Atopic Dermatitis
2018	A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Trade Name in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
2018	A multicenter, randomized, double-blind, trade name-controlled, parallel-group study to evaluate the efficacy and safety of trade name in adult subjects with moderate to severe chronic plaque psoriasis
2018	A multicenter, open-label study to assess the long-term safety, tolerability, and efficacy of trade name in adult subjects with moderate to severe chronic plaque psoriasis
2018	A randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of trade name in combination with topical corticosteroids in subjects with moderate-to-severe atopic dermatitis who are candidates for systemic therapy
2018-2021	A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of Trade Name in Subjects with Moderate-to-Severe Plaque Psoriasis
2018-2020	A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of sub-cutaneous Trade Name in subjects of body weight 90 kg or higher with moderate to severe chronic plaque-type psoriasis

2018-2020	A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Trade Name Compared to Trade Name for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis who are Candidates for Systemic Therapy
2018-2020	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- And Active Comparator-Controlled, Parallel-Group Study To Evaluate The Efficacy And Safety Of Trade Name In Adult Subjects With Moderate To Severe Chronic Plaque Psoriasis
2018-2021	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Trade Name in Adult Patients with Moderate to Severe Atopic Dermatitis
2018-2022	A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of trade name in Patients with Moderate-to-Severe Plaque Psoriasis
2018-2022	A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Trade Name in Adult Patients with Moderate to Severe Atopic Dermatitis
2018 – 2019	A Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled Study To Evaluate The Safety And Efficacy Of Dose A And Dose B Trade Name In Patients With Papulopustular Rosacea
2017 – 2018	A Phase 1b Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study Assessing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Trade Name in Subject with Atopic Dermatitis
2017 – 2018	A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Trade Name versus Vehicle in Subjects 2 years of age or older with Cutaneous Common Warts
2017	A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of Trade Name monotherapy in subjects with moderate-to-severe atopic dermatitis who are candidates for systemic therapy
2017	A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of Trade Name in Subjects Who are Asymptomatic At Risk for Developing Alzheimer’s Dementia
2017-2023	A multicenter, open label study to assess the safety and efficacy of Trade Name for maintenance in moderate to severe plaque type psoriasis
2017	Multicenter, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Trade Name in Patients from 6 to Less than 18 Years of Age with Moderate-to-Severe Plaque Psoriasis
2017 – 2018	A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of Trade Name and Trade Name for the Treatment of Moderate to Severe Plaque-type Psoriasis

- 2016 A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of Trade Name in Mild Alzheimer's Disease Dementia (The DAYBREAK Study)
- 2016 – 2018 A multicenter, randomized, double-blind, placebo-controlled, 52-weeks study to demonstrate the efficacy, safety and tolerability of subcutaneous trade name injections with 2 mL pre-filled syringes (300 mg) in adult subjects with moderate to severe plaque psoriasis
- 2016 – 2018 A randomized, double blind, parallel group, placebo-controlled trial to study the efficacy and safety of two oral doses of Trade Name administered twice daily for twelve weeks to subjects with moderate to severe plaque psoriasis
- 2016 – 2017 A Phase 3, Multicenter, Randomized, Double-blind Placebo-controlled Study Evaluating the Efficacy and Safety of Trade Name Delivered via a Self-Dose Device in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis
- 2016 A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of Trade Name in Subjects with Moderate-to-Severe Plaque Psoriasis
- 2016 – 2019 A multi-center, double-blind, randomized, vehicle-controlled study of efficacy and safety of topical Trade Name in the treatment of mild to moderate distal subungual onychomycosis (DSO)
- 2016 A Phase 2, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, and Efficacy of Trade Name in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis who are Candidates for Systemic Therapy or Phototherapy
- 2016 – 2016 A Randomized, Double-Blind Study to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of Trade Name for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris
- 2016 – 2018 A 52-week, multicenter, randomized, double-blind study of Trade Name (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator's Global Assessment after 12 weeks of treatment, compared to Trade Name, and to assess Long-term safety, tolerability, and efficacy in subjects with moderate to severe plaque Psoriasis
- 2016 – 2017 Trade Name Versus Trade Name in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque Psoriasis to Assess Safety and Efficacy After 16 Weeks of Treatment and After Inadequate Trade Name Treatment Response
- 2016 – 2018 Trade Name Versus Trade Name and Placebo Comparators in a Randomized Double-Blind Trial for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2
- 2015 An Open-Label, Long-Term Extension Study to Evaluate the Safety of Trade Name Cream, 1% Applied Twice Daily in Subjects with Acne Vulgaris
- 2015 – 2016 A Double-Blind Extension Study to Evaluate the Post Treatment Safety and Duration of Clinical Effect of Trade Name in Subjects Who Completed Either the Core 18 or Core 19 Study

- 2015 – 2018 A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Trade Name Cream, 1% Applied Twice Daily for 12 Weeks in Subjects with Facial Acne Vulgaris
- 2015 – 2017 An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Trade Name topical solution, 5% in the Treatment of Onychomycosis of the Toenail in Pediatric Subjects Ages 6 to 16 Years and 11 Months
- 2015 – 2016 An Open-Label Study Assessing Long-Term Safety of Trade Name Subjects with Primary Axillary Hyperhidrosis
- 2015 – 2016 A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Efficacy and Safety Study of Trade Name in Subjects with Axillary Hyperhidrosis
- 2015 – 2015 A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Safety and Efficacy of Trade Name for the Reduction of Central Abdominal Bulging Due To Subcutaneous Fat in Non-Obese Subjects
- 2015 – 2017 A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Trade Name Dosing Regimens in Patients with Moderate-to Severe Plaque Psoriasis
- 2015 – 2017 A Long Term Safety and Efficacy Study of Trade Name Cream in Subjects With Acne Vulgaris
- 2015 – 2017 Efficacy and Safety of Trade Name Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp or Approximately 250 cm² on the Chest
- 2015 – 2016 A Phase 2 Study Comparing the Occurrence of Actinic Keratosis on the Face in High-Risk Individuals After Cryotherapy + Photodynamic Therapy with Trade Name Topical Solution + Blue Light Versus Cryotherapy + Vehicle Topical Solution + Blue Light
- 2015 – 2018 An Open-label Study Evaluating the Long-term Efficacy, Quality of Life, and Safety of Trade Name Capsules Administered Without Food in Patients With Severe Recalcitrant Nodular Acne
- 2015 A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of Trade Name in Subjects with Amnesic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)
- 2015 A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of Trade Name with a Long Term Double-Blind Extension in Subjects with Mild to Moderate Alzheimer's Disease
- 2014 – 2015 Twelve Month Follow-up Evaluation of Subjects Participating in (A Phase 3 Study of Photodynamic Therapy with Trade Name Topical Solution Plus Blue Light Versus Topical Solution Vehicle Plus Blue Light For the Treatment of Actinic Keratoses on the Upper Extremities)

- 2014 – 2016 A Randomized, Double-Blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Trade Name and Trade Name in Patients with Moderate to Severe Chronic Plaque-type Psoriasis
- 2014 – 2017 A Randomized, Multicenter, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg per Day Trade Name Compared to Placebo in the Treatment of Acne Vulgaris
- 2014 – 2016 A Phase 2 Multicenter, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Trade Name for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis
- 2014 – 2017 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Trade Name Oral Tablets in the Treatment of Patients with Distal and Lateral Subungual Onychomycosis of the Toenail
- 2014 – 2016 A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Trade Name for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Trade Name
- 2014-2020 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study Evaluating the Efficacy and Safety of Trade Name for the Treatment of Subjects with Moderate to Severe Plaque-Type Psoriasis with Randomized Withdrawal and Retreatment
- 2014-2020 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study Evaluating the Efficacy and Safety of Trade Name for the Treatment of Subjects with Moderate to Severe Plaque-Type Psoriasis
- 2014 – 2016 Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy with Trade Name Topical Solution Plus Blue Light Versus Topical Solution Vehicle Plus Blue Light For the Treatment of Actinic Keratoses on the Upper Extremities)
- 2014 – 2016 A Randomized, Double-Blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Trade Name Biologic and Trade Name Biologic in Patients with Moderate to Severe Chronic Plaque-Type Psoriasis
- 2014 – 2016 A 52-Week, Multicenter, Randomized, Double-Blind Study of Subcutaneous Trade Name to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index at 16 Weeks of Treatment Compared to Trade Name and to Assess Long-Term Safety, Tolerability and Efficacy in Subjects with Moderate to Severe Plaque Psoriasis
- 2014 – 2015 A Long-Term Safety and Efficacy Study of Trade Name Cream 1.0% in Patients with Persistent Erythema Associated with Rosacea
- 2014 – 2015 A Phase 3 Study of Photodynamic Therapy with Trade Name Topical Solution Plus Blue Light Versus Topical Solution Vehicle Plus Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities

- 2014 – 2016 A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Trade Name for Treatment of Nail Psoriasis in Patients with Chronic Plaque Psoriasis
- 2014 – 2015 A Phase 2 Randomized, Double-Blind, Vehicle-Controlled, Dose-Ranging Study to Investigate the Efficacy and Safety of Trade Name in Patients with Mild to Moderate Onychomycosis
- 2013 – 2014 A Follow-up Evaluation of Study Subjects Treated in a previous Protocol -the Phase 3 Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy and Safety of Trade Name in Patients with Severe Recalcitrant Nodular Acne
- 2013 – 2019 A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Trade Name to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period
- 2013 – 2014 Safety and Efficacy of Escalating Doses of Trade Name for Two or Three Consecutive Days When Used on Full Face, Full Balding Scalp or Approximately 250 cm² on the Chest in Subjects with Actinic Keratosis.
- 2013 – 2014 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Trade Name Oral Tablets in the Treatment of Patients with Moderate to Severe Interdigital Tinea Pedis
- 2013 – 2014 A Phase 2B, Multi-Site, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study of the Efficacy, Safety, Local Tolerability, and Pharmacokinetics of 2 Dose Strengths and 2 Regimens of Trade Name Ointment in Subjects with Chronic Plaque Psoriasis
- 2013 – 2017 A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Trade Name Drug and to Assess Safety, Tolerability and Long-Term Efficacy up to 132 Weeks in Subjects with Moderate to Severe Nail Psoriasis
- 2013 – 2014 A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Three Once-Daily Trade Name Topical Gels Versus Vehicle Administered for 12 Weeks to Subjects with Papulopustular Rosacea
- 2014 – 2017 A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of Trade Name with a Long Term Double-Blind Extension in Subjects with Mild to Moderate Alzheimer's Disease
- 2013 – 2019 A 52-Week, Phase 3, Randomized, Active Comparator and Placebo Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Trade Name Drug, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis
- 2012 – 2013 A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multiple Site, Clinical Study to Evaluate the Bioequivalence of Two Trade Name Cream Formulations in Patients

with Actinic Keratosis

- 2012 – 2014 Safety and Efficacy of Trade Name Solution, 10% with Two Dosing Regimens in Distal Subungual Onychomycosis of the Toenails: A Randomized, Double-Blind, Vehicle-Controlled, Phase 2b/3 Study
- 2012 – 2013 A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of Trade Name and Trade Name vehicle Gel in the Treatment of Acne Vulgaris
- 2012 – 2013 A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical Trade Name Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
- 2012 – 2013 A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Generic Drug to Reference Listed Drug in the Treatment of Tinea Pedis
- 2012 – 2013 A Parallel-Group, Vehicle Controlled, Randomized, Double-Blind Study of the Efficacy and Safety of Trade Name and Trade Name in Subjects with Seborrheic Dermatitis
- 2012 – 2015 A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Trade Name Compared with Placebo and Trade Name in Subjects With Moderate to Severe Plaque Psoriasis
- 2012 – 2017 A Multicenter, Double-Blind, Randomized Withdrawal Extension Study of Subcutaneous Trade Name Drug in Prefilled Syringes to Demonstrate Long-Term Efficacy, Safety and Tolerability up to 2 Years in Subjects with Moderate to Severe Chronic Plaque-Type Psoriasis Completing Preceding Psoriasis Phase III Studies with Trade Name Drug
- 2012 – 2013 A Randomized, Multi-Center, Investigator-Blind, Vehicle- and Active- Controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of Trade Name Cream Applied Once Daily in Subjects with Moderate to Severe Acne Vulgaris
- 2012 – 2013 A Randomized, Multicenter, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Different Doses of a Trade Name, Compared to Placebo in Treatment of Facial Acne Vulgaris
- 2012 – 2015 A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects with Moderate to Severe Psoriasis
- 2012 – 2013 A Randomized, Double-Blind, Placebo-Controlled, 4-week Trial of Trade Name in Patients with Moderate to Severe Plaque Psoriasis
- 2011 – 2013 A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Trade Name in Subjects with Moderate to Severe Acne Vulgaris
- 2011 – 2013 A Phase 3 Randomized, Double-blind, 12-Week Vehicle-controlled, Parallel-group Study Assessing the Efficacy and Safety of Trade Name Cream Versus Vehicle Cream in Subjects with Papulopustular Rosacea, Followed by a 40-Week Investigator-blinded

Extension Comparing the Long-Term Safety of Trade Name Cream Versus Trade Name Gel

- 2011 – 2012 A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Generic Name Topical Gel 0.1%/2.5% to Trade Name Topical Gel 0.1%/2.5%, and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris
- 2011 – 2012 A Randomized, Placebo-Controlled Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of Trade Name Topical When Applied Twice Daily in Subjects with Psoriasis Vulgaris
- 2011 A Randomized, Double-Blind, Placebo Controlled, Multicenter Study of Subcutaneous Trade Name to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-Term Efficacy up to One Year in Subjects with Moderate to Severe Chronic Plaque-Type Psoriasis
- 2011 – 2013 A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Multicenter Study of Subcutaneous Trade Name to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Trade Name, and to Assess the Safety, Tolerability and Long-Term Efficacy up to One Year in Subjects with Moderate to Severe Chronic Plaque-Type Psoriasis
- 2011 – 2012 A Proof of Concept (PoC) Study to Evaluate the Safety, Tolerability, and Efficacy of 12 Week Administration of Trade Name Ointment in Rosacea Patients
- 2011 – 2013 A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trail to Evaluate Trade Name for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis
- 2011 – 2012 A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Assess the Safety of Trade Name Gel Applied Topically Once Daily in Subjects with Moderate to Severe Facial Erythema Associated with Rosacea
- 2011 A Double-Blind, Randomized, Parallel-design, Vehicle-controlled, Multicenter Trial Comparing Generic to Trade Name and Benzoyl Peroxide, 5% Topical Gel and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris
- 2011 – 2012 A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison of Trade Name Foam VS Foam Vehicle and an Evaluator Blinded Comparison of Trade Name Cream in Subjects with Interdigital Tinea Pedis
- 2011 – 2012 A Multi-center, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel Group Study Comparing the Efficacy and Safety of Trade Name 40 mg Tablets versus Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions in Subjects with Acne Vulgaris
- 2011 – 2016 A Phase 3, Multi-Site, Open-Label Study of the Long Term Safety and Tolerability of 2 Oral Doses of Trade Name in Subjects with Moderate to Severe Chronic Plaque Psoriasis

- 2011 A Phase 3 double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of Trade Name in Subjects with Tinea Pedis
- 2011 – 2013 A Phase 3, Multi-Site, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of 2 Oral Doses of Trade Name Medication in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- 2010 – 2015 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Trade Name In Subjects With Moderated to Severe Plaque Psoriasis
- 2010 – 2013 A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled trial of a Trade Name Medication Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis Including Those Previously Treated with Biologic Anti-TNF α Agent(s)
- 2010 – 2011 A Multicenter, Randomized, Vehicle-controlled, Double-blind, Parallel Group Study of Efficacy and Safety of Topical Aerosol Applied Twice Daily for 8 Weeks in Subjects with Plaque-type Psoriasis
- 2010 – 2011 An Open-Label Evaluation of the Adrenal Suppression Potential of Trade Name Lotion 0.05% in the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric Subjects
- 2010 – 2013 A Randomized, Double-Blind, Vehicle-controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Trade Name Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults
- 2008 – 2010 A Phase 2B, Multicenter, Treatment-Arm Blind, Safety and Efficacy 28-Week Extension Study of Trade Name in Subjects Who Completed the Treatment Phase of the Core Study
- 2010 – 2011 Trade name topical suspension compared to betamethasone dipropionate in the topical suspension vehicle, calcipotriol in the topical suspension vehicle and the topical suspension vehicle alone in psoriasis vulgaris. A national, multi-centre, prospective, randomised, double-blind, 4-arm, parallel group, 8-week study in subjects with psoriasis vulgaris on the non-scalp regions of the body (trunk and/or limbs).
- 2010 – 2011 A 4-Week Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Investigating the Efficacy and Safety of Trade Name Gel Applied Topically Once Daily (QD), and Trade Name Gel Applied Topically Once Daily (QD) or Twice Daily (BID), in Subjects with Moderate to Severe Facial Erythema Associated with Rosacea
- 2010 – 2012 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of Trade Name Nail Lacquer 3% in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Weeks
- 2010 – 2011 A Phase 2, Multicenter, Randomized, Double-Blind, Dose-Ranging Study to Evaluate Trade Name Versus Placebo in the Treatment of Severe Acne Vulgaris with Nodules
- 2010 An Evaluation of the Safety and Effectiveness of Trade Name Device in the Treatment of Mild-to-Moderate Acne
- 2010 – 2011 A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Trade

Name Drug in Healthy Subjects and Subjects with Moderate to Severe Atopic Dermatitis

- 2010 – 2016 A Multicenter Extension Trial of Subcutaneously Administered Trade Name in Patients With Moderate to Severe Chronic Plaque Type Psoriasis
- 2010 – 2012 A Randomized, Double-blind, Vehicle- and Placebo-Controlled, Multicenter Trial in Patients with Mild to Moderate Distal Subungual Toenail Onychomycosis to Investigate the Efficacy, Tolerability, and Safety of Twice Daily Application of Trade Name for 48 Weeks
- 2009 – 2010 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Brand Name Compared with Vehicle Administered Topically in the Treatment of Distal Subungual Onychomycosis of the toenail
- 2010 – 2013 A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled trial of Trade Name Medication, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis
- 2010 – 2011 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose Ranging Study of Subcutaneously Administered Trade Name, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients with Moderate to Severe Chronic Plaque-type Psoriasis
- 2010 – 2012 A Subject Blinded Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Iontophoretic Application of Trade Name Gel in Subjects with Distal Subungual Onychomycosis in the Great Toenail
- 2009 – 2010 Randomized, Double-blind, Vehicle-Controlled, Multicenter, Parallel-Group Study to Investigate Safety and Efficacy of Trade Name Foam Topically Applied Twice Daily in Subjects with Papulopustular Rosacea
- 2009 – 2011 A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Safety and Efficacy of Trade Name Topical Solution Versus Vehicle in Subjects with Mild to Moderate Onychomycosis of the Toenails
- 2009 – 2016 A 10-Year, Post-marketing, Observational, Registry to Assess Long Term Safety of Trade Name in Adult Patients with Chronic Plaque Psoriasis
- 2009 – 2010 A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Trade Name Foam, In Subjects With Acne Vulgaris
- 2009 – 2011 A Double-Blind, Randomized, Phase III, Parallel Group Study Evaluating the Efficacy and Safety of Trade Name in Patients With Severe Recalcitrant Nodular Acne
- 2009 – 2011 A randomized, double-blind, placebo controlled, multicenter regimen finding study of subcutaneously administered trade name, assessing Psoriasis Area and Severity Index (PASI) response in patients with moderate to severe chronic plaque-type psoriasis
- 2009 A Phase 4, Open-Label, Multicenter, Community-based, 12-Week Trial Assessment of Effectiveness, Safety, and Subject Satisfaction With Trade Name Capsules When used as Monotherapy or as Add-On Therapy to Existing Topical Regimens for the Treatment of

Rosacea

- 2009 A Four-Week, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Trade Name Ointment Twice Daily in the Treatment of Adults with at Least Moderate Atopic Dermatitis
- 2009 – 2010 An Open-Label Study to Evaluate the Safety, Tolerability, and Local Terbinafine Concentrations of Trade Name in the Toenail of Both Healthy Subjects and Patients With Distal Subungual Onychomycosis
- 2009 A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Duration-Finding, Study Evaluating the Efficacy and Safety of Two Week and Four Week Once Daily Treatment of Investigational Cream 1% in Patients with Tinea Pedis
- 2009 – 2010 A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Investigational Ointment, 1%, versus Oral Trade Name in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin Resistant *Staphylococcus aureus*
- 2009 – 2010 An Open-Label Study to Evaluate the Safety, Efficacy, Tolerability, and Local Pharmacokinetics of Trade Name Implant in the Treatment of Distal Subungual Onychomycosis of the Fingernail
- 2009 – 2010 A Usability Study of a Trade Name Device on Adult Subjects with Acne
- 2009 A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Clinical Study to Evaluate the Bioequivalence of Generic Cream 5% Compared to Trade Name Cream 5% in Patients with Actinic Keratosis
- 2009 A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the safety and Bioequivalence of Generic Gel and Trade Name Gel and Compare Both Active Treatments to a Vehicle Control in the Treatment of Actinic Keratosis
- 2008 – 2011 Assessment and Tracking of Long-term Trade Name Medication.
- 2008 – 2010 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-controlled, Dose-Ranging, Efficacy and Safety Study of Brand Name in Subjects with Moderate to Severe Plaque Type Psoriasis (Core Study)
- 2008 – 2009 A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of Brand Name in Subjects with Tinea Pedis
- 2008 A Randomized, Double-Blind, Placebo-Controlled, Single-and Multiple Dose, Dose-Escalation Trial of Brand Name in Psoriatic Subjects, Followed by an Expansion Phase
- 2008 – 2010 A Phase 4, Open-Label Study to Assess the Long-Term Safety of Brand Name Foam, 2% in the Treatment of Seborrheic Dermatitis
- 2008 – 2010 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Efficacy and Safety of 4 Dose Regimens of Generic in Subjects with Distal Subungual Onychomycosis

2008	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Brand Name to Brand Name and Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis
2008	A Phase 3, Multi-Center, Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceding Psoriasis Study With Brand Name
2008 – 2010	A Randomized, Double-Blind, Vehicle-Controlled, Dose-Ranging Study of Brand Name Topical Cream for the Treatment of Superficial Basal Cell Carcinoma
2008	A Randomized, Double-Blind, Vehicle-Controlled, Dose-Ranging Study of Brand Name
2008	An observational study of cure status in a subset of subjects with psoriasis from a previous protocol
2008 – 2009	A Phase 2B, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Dose Regimens with Oral Brand Name in the Treatment of Subjects with Chronic Plaque Psoriasis
2008 – 2009	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Two Doses of Brand Name in Patients with Atopic Dermatitis
2008	A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety and Efficacy of Brand Name Foam, 0.005% versus Vehicle Foam in Subjects with Plaque-Type Psoriasis
2008 – 2009	A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Generic Cream to Brand Name Cream and Both Active Treatments to a Vehicle Control in the Treatment of Actinic Keratosis of the Face or Scalp
2008 – 2012	Efficacy and Safety of Alitretinoin in the Treatment of Severe Chronic Hand Eczema Refractory to Topical Therapy
2008	A Randomized, Double-blind study to Evaluate the Efficacy of a New Oral Low Dose Formulation of Brand name as Compared to Placebo in the Treatment of Moderate to Severe Inflammatory Facial Acne vulgaris
2008 – 2009	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Two Dosing Regimens of Brand Name to Placebo in Subjects with Moderate to Severe Chronic Plaques Psoriasis
2007 – 2010	A Multicenter, Open-label Study to Assess the Efficacy and Safety of Brand Name Therapy in Patients with Plaque Psoriasis Who Had an Inadequate Response to Brand Name
2007 – 2009	A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Brand Name Ointment 0.1% to Brand Name Ointment 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Atopic Dermatitis
2007 – 2008	A Phase 2 Study of the Dose-Effect of Brand Name Ointment in Patients with Plaque-type Psoriasis.

- 2007 – 2009 A Phase 2B, Multi-Center, Double-Blind, Randomized, Dose-Ranging Clinical trial to Evaluate Brand Name in the Treatment of Moderate to Severe Acne Vulgaris with Nodular Involvement.
- 2007 – 2008 A Clinical Assessment of Combination Therapy with Brand Name 0.3% and Brand Name gel in Subjects with Acne Vulgaris.
- 2007 – 2008 A Double-Blind, Randomized, Parallel-group Placebo-Controlled, Multi-center Study to Evaluate the Safety and Clinical Equivalence of Generic Cream 5% to Brand Name Cream 5% and both Active Treatments to a Vehicle Control in the Treatment of Actinic Keratosis of the Face or Scalp.
- 2007 – 2009 A Multi-center, Placebo-Controlled, Double-Blind study to Evaluate the Safety and Efficacy of Brand Name in the Treatment of Distal Subungal Onychomycosis of the Toenail
- 2007 – 2008 A Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center study to Evaluate the Safety and Clinical Equivalence of Generic 1% gel, Brand Name 1% gel, and both Active Treatments to a Vehicle Control in the Treatment of Inflammatory Rosacea lesions.
- 2007 A randomized, double-blind, active-controlled, multi-center, parallel-group dose-ranging study assessing the safety and efficacy of Brand Name versus Brand Name among immunocompetent patient with an acute episode of herpes zoster
- 2007 Two Multi-center, Randomized, double-blind, parallel group comparison studies to demonstrate the efficacy and safety of Brand Name lotion, compared with vehicle lotion in subjects with acne vulgaris
- 2007 An Open-Label, Multi-Center, Uncontrolled, Single-Group Assignment, Long-Term safety Study of Trade name cream in subjects with Actinic Keratosis
- 2007 An Investigator-Blinded Study Evaluating the Efficacy and Safety of Four Brand name Treatment Regimens With Placebo and Brand name in the Treatment of Onychomycosis of the Toenail.
- 2007 A Single Center, Open Label Study to Evaluate the Tolerability of test placebo product in Healthy Subjects
- 2007 A Pilot Multi-Center, Double-Blind, Randomized, Parallel-Group Study Comparing Generic cream to Brand Name cream in the Treatment of Actinic Keratosis of the Face or Scalp.
- 2007 A Multicenter Dose-Escalation and Dose-Response Study of Photodynamic Therapy with Brand name cream in patients with Moderate to Severe Acne Vulgaris in the Face
- 2007 Early Diagnosis of Melanoma using Expression Profiling and Non-invasive sampling of Skin Cells

2007	A Multicenter, Open Registry of Patients with Plaque Psoriasis Who are Candidates for Systemic Therapy Including Biologics
2006 – 2007	A randomized, double-blind, parallel-group, multicenter, dose-response, vehicle-controlled study of the safety and efficacy of brand name in the treatment of mild to moderate distal subungual onychomycosis of the toenail
2006 – 2007	A randomized, double-blind, vehicle-controlled, Multicenter, parallel group study to assess the efficacy safety, and tolerability of topical brand name formulation for 24 or 48 weeks of treatment in patients with mild to moderate toenail onychomycosis
2006 – 2007	Dose-effect study of brand name in Rosacea
2006 – 2007	A double-blind, randomized, Multicenter, vehicle-controlled, dose-ranging study of generic cream to determined the safety and efficacy in subjects with plaque psoriasis receiving three weeks of treatment
2006 – 2007	A Phase III Randomized, evaluator-blind, parallel group study of the safety and efficacy of brand name tablets, brand name capsules and placebo in the treatment of onychomycosis of the toenail
2006	Observational post-marketing safety surveillance registry of brand name for the treatment of psoriasis
2006	Dose-effect study of brand name in Rosacea
2006 – 2007	A Phase 3, Multi-center, randomized, double-blind, vehicle-controlled, 4-arm parallel group comparison study comparing the efficacy and safety of brand name, brand name vehicle, generic medication, and generic gel in the treatment of moderate to severe acne vulgaris
2006 – 2007	A Phase 2 trial of the safety, local tolerability, and efficacy of chronic daily ungula application of study medication (nail lacquer) to subjects with onychomycosis of the great toenail
2006 – 2007	A randomized, double-blind, active-controlled, vehicle-controlled, subject initiated study comparing efficacy and safety of study medication versus generic cream for treatment of recurrent herpes simplex labialis
2006	A Multicenter, randomized, double-blind study of the safety and efficacy of emulsion formulation generic foam versus vehicle foam, Brand Name ointment, and vehicle ointment in the treatment of mild to moderate plaque-type psoriasis
2006 – 2010	A Multicenter, open-label, controlled phase II study to evaluate safety and immunogenicity of smallpox vaccine in 18-40 year old subjects with diagnosed Atopic dermatitis
2006 – 2011	A Phase 3, Multicenter, Randomized, double-blind, placebo controlled trial evaluating the efficacy and Safety of investigational medication in the treatment of subjects with moderate to severe plaque-type psoriasis

- 2006 A Clinical evaluation of Brand name Cream 0.1% indicated for the topical treatment of patients with acne vulgaris, who do not want to or are unable to participate in the IPLEDGE program
- 2006 – 2011 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Brand Name in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis
- 2006 A Comparison of Brand name Gel, 0.1% vs. Brand Name Cream, 0.1% vs. Brand Name Gel, 0.1%, 6-Week Treatment Switched to Brand Name Cream, 0.1%, 6-weeks Treatment in Patients with Acne Vulgaris
- 2006 A Four Week Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Onset Efficacy of Brand Name 40 mg Administered Once Daily in Conjunction with Brand Name Gel 15% for the Treatment of Rosacea
- 2006 A Randomized, Double-Bind, Vehicle-Controlled Study of the Safety and Efficacy of Brand Name Foam, 2%, Versus Generic 2% Cream in the Treatment of Seborrheic Dermatitis
- 2006 A Randomized, Evaluator Blinded, Vehicle-Controlled, Multi-Center Study of the Safety and Efficacy of 4% Trade Name Cream, Versus its Vehicle Cream, Versus Brand Name Treatment of Actinic Keratosis
- 2006 A 16-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Dose Response Clinical Trail Designed to Determine the Safety, Effectiveness and Tolerability of 5, 10 and 20 mg of Brand Name Capsules Administered Once Daily Versus Placebo Capsules Administered Once Daily in Patients with Acne
- 2006 A Phase 4, Open-Label, Multicenter, Community-based, 4-week Trial Assessing Efficacy, Tolerance to Treatment, and subject Satisfaction With brand name spray, when Used as Mono-therapy or a s Add-on therapy to Existing Systemic or Topical Antipsoriatic Agents for the Treatment of Moderate to Severe Plaque Psoriasis.
- 2005 An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Brand Name medication in Adults with Psoriasis Involving the Fingernails
- 2005 A Phase 2, Multi-Center, Randomized, Evaluator-Blind, Vehicle controlled, 6-arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of Brand Name Gel Vs Generic 1% Vs Generic 2.5% gels in the Treatment of Acne Vulgaris
- 2005 A Phase 2B Efficacy and safety Study of Four Brand Name Topical Gel Formulations of Anti-Fungal Agents, Vs Vehicle in the Treatment of Tinea Unguim
- 2005 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center study Comparing Generic cream Vs Marketed Generic Cream and Both Active Treatments to A vehicle Control in the Treatment of Tinea Versicolor
- 2005 A Randomized, Double-Bind, Vehicle-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied Brand Name vs. Vehicle for the Treatment of Adult Subjects with Mild to Moderate Atopic Dermatitis

2005	A 16-week, Multicenter, Randomized, Double-Bind, Placebo-Controlled, Sequential Dose Response Clinical Trial Designed to Determine the Safety, Effectiveness and Tolerability of 5, 10, and 20 mg Brand name capsules administered Once Daily Vs Placebo Capsules Administered Once Daily in Patients with Acne
2005 – 2009	An Epidemiologic study of Psoriasis outcomes and Safety Events in Patients with Chronic Moderate to Severe Plaques Psoriasis
2005	An Open-label Safety and Pharmacokinetic Study of Brand name Cream, for One, Two or Three Treatment Cycles to surface Area Grater than 25 cm ² with Actinic Keratosis.
2005	A Randomized, Double-Blind, Vehicle-Controlled Study of the safety and Efficacy of Brand name foam Vs. Generic cream in the treatment of seborrheic dermatitis.
2005	Safety and Efficacy Evaluation of Generic Gel Vs. Vehicle in the Treatment of Mild to Moderate Acne Vulgaris
2005	A multi-Center, Double-Blind, Randomized, Vehicle Controlled, Parallel-Group Study Comparing Generic Cream to Brand Name Cream and Both Active Treatments to a Vehicle Control in the Treatment of Actinic Keratosis of the Face or Scalp
2005	A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Effect of Brand Name Oral Capsules Administered Once Daily in Conjunction with Brand Name for the Treatment of Rosacea
2005	A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied Brand Name Gel vs. the Vehicle for the Treatment of Pediatric Subjects with Mild to Moderate Atopic Dermatitis
2005	Evaluation of Hand and Nail Cream on the condition of the Hands and Fingernails
2005	Twelve Month Follow-Up Evaluation of Subjects Participating in: A Phase II, Multicenter, Randomized, Investigator Blinded, Parallel-Group Study of Photodynamic Therapy in the Treatment of Moderate to Severe Facial Acne Vulgaris with Topical Solution Plus Light versus Vehicle Plus Light
2005	A Randomized, Double-Blind, Parallel Group, Multicenter, Phase 3 Extension, Efficacy and safety Study of Brand name vs. placebo combined with oral Medication in the treatment of onychomycosis
2005	An Open Label, Single Group, Multicenter, Phase III Extension Study to Assess the Maintenance Use of Brand Name in the treatment of Onychomycosis
2005	Efficacy and Safety of Brand Name Gel Compared to Brand Name Gel in the Treatment of Rosacea
2005	A Randomized, Double-Blind, Parallel-Group, Multicenter, Dose-Response, Vehicle-Controlled Study of the Safety and Efficacy of a Brand Name in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail

2004	A Phase 3B, Open-Label effectiveness and safety study of topical cream in the treatment of Actinic Keratosis
2004	A Phase 2, Multicenter, randomized, investigator blinded, parallel-group study of photodynamic therapy in the treatment of moderate to severe facial acne vulgaris with topical solution plus light versus vehicle plus light
2004	A Randomized, Double-blind, Double-dummy, Multicenter non-inferiority Phase III study to assess the safety and efficacy of topical ointment, applied twice daily, versus oral medication in the treatment of secondarily-infected dermatoses
2004	A 6 week randomized, Multicenter, Double-blind, Placebo-controlled, Parallel group study to investigate the efficacy and safety of brand name cream in patients with mild to moderate chronic hand dermatitis, followed by a 6 week open label phase to assess the safety of a brand name cream
2004	A Multicenter, Open-label, Prospective study to evaluate the effectiveness and safety of a generic medication in the treatment of subjects with Psoriasis
2004	A Three-stage, Modified-blind, Dose-escalating study to assess efficacy and safety of study medication gel applied 3 times per week for 4 weeks for the treatment of common warts in adults
2004	Phase 3 Vehicle-controlled, Double-blind study to assess the safety and efficacy of brand name medication for the treatment of Molluscum Contagiosum in pediatric subjects
2004	Phase 2, Multiple-Dose study to assess safety and efficacy of a topical study cream applied 1, 2 and 3 times a week for 8 weeks in subjects with Actinic Keratosis
2004	A Double-blind, Randomized, Parallel-group, Vehicle-controlled, Multi-center study to evaluate the safety and clinical equivalence of a generic medication to a brand name medication in the treatment of Tinea Pedis
2004	A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group clinical trial to determine the effects of a generic medication administered once daily versus a placebo controlled administered once daily for the treatment of Rosacea
2004	A Multicenter, Randomized, Double-blind, Parallel group study to evaluate the safety and efficacy of a fixed combination of a brand name gel compared to each monad and topical gel vehicle in subjects with acne vulgaris
2004	A Phase 2, Multicenter, Double-Blind, Randomized, Dose-Ranging Evaluation of the Efficacy of a Topical Gel Following Repeated Topical Application on Subjects with Acne Vulgaris
2004	A Multicenter Efficacy and Safety Study of a Topical Gel Combination and Maintenance Therapy of Moderate-to-Severe Papulopustular Rosacea:
2004	an Open- Label, 12-Week Study of Combined Topical Gel and Systemic Medication Followed by a Double-Blind, Randomized, 24-Week Comparison of Topical Gel With its Vehicle in Maintaining Remissions of Rosacea

2004	A Long Term Safety and Efficacy Study of a Fixed Combination of a Topical Gel in Subjects with Acne Vulgaris
2004	A Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Three Dose Levels of a Medication in the Treatment of Chronic Plaque Psoriasis
2004 – 2011	A Multicenter International Observational Study of the Long-Term Safety of Brand Name Medication
2004	A 26-Week, Randomized, Multicenter, Parallel-Group, Double Blind, Vehicle-Controlled Study to Evaluate the Incidence of Atopic Dermatitis Flares When Cream is Used at the First Signs and/or Symptoms of Atopic Dermatitis and its Safety and Tolerability in Adults 18 Years of Age and Older
2004	A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled Multi-Center Study to Evaluate the Safety and Equivalence of a Generic Cream to Brand Name Cream
2003	Efficacy and Safety of Brand and Shampoo in the Prevention of Relapse of Seborrheic Dermatitis of the Scalp
2003	A Phase 3B, Open-Label, Multicenter Study to Evaluate the Safety of a Subcutaneously Administered Brand Name Medication in Adults With Moderate to Severe Plaque Psoriasis, Including Those Who are Receiving Concomitant Anti-Psoriatic Therapies or Have Recently Transitioned From Systemic Therapies.
2003	The Efficacy and Safety of Combination Brand Name Gel Generic Capsules, Compared to Brand Name Gel vehicle With Generic Capsules in Subjects With Acne Vulgaris.
2003	A Phase 2, Randomized, Double Blind, Placebo-Controlled, Parallel Study of Single and Multiple Dose Regimes With Subcutaneous Study Medication in Subjects With Moderate to Severe Psoriasis.
2003	A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Brand Name Therapy Followed by Multiple Regimens of Brand Name Medication in Subjects with Plaque-Type Psoriasis.
2003	A Multiple Center, Randomized, Evaluator Blind Study of the Safety and Efficacy of a Brand Name Cream and Two Generic Creams Versus its Three Paired Active Ingredient Creams in the Treatment of Post-Inflammatory Hyper-Pigmentation.
2003	Randomized, double blind, parallel group, Multicenter, vehicle-controlled study of a generic cream once daily and twice daily in the treatment of plaque-type psoriasis.
2003	Multi-Center, Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Efficacy and Safety of 3 Doses of Brand name Capsules in the Treatment of Plaque Psoriasis for 8 Weeks.
2003	A Phase 3, Randomized, double-Blind, Parallel Group, Multicenter, Efficacy and Safety Study of Study medication vs Vehicle for the Treatment of Onychomycosis

2003	A Multicenter, Open Label Study to Observe the Effect of Brand name medication on Joint and skin Disease in Subjects with Psoriatic Arthritis
2003	A Double-Blind, Randomized, Vehicle-Controlled, Multicenter Parallel Study to Assess the Efficacy and Safety of a combination Topical Gel Product in the Treatment of Moderate to Severe Seborrheic Dermatitis.
2003	A Randomized, Evaluator Blind, Vehicle Controlled, Parallel Group Dose Ranging Study of the Safety and Efficacy of Four Concentrations/Application Frequencies of Topical Cream Versus Its Vehicle in the Treatment of Plaque Psoriasis
2003	An Open-Label Study of the Safety and Efficacy of a Topical Patch in the Treatment of Distal Subungual Onychomycosis of the Toenails
2003	Evaluation of Systemic Exposure During Topical Patch Treatment in Subjects with Distal Subungual Onychomycosis
2003	A Multi-Center, Phase 3, Randomized, Double-Blind, 4 Arm Clinical Trial to Compare the Safety and Efficacy of Brand Name Gel in the Treatment of Acne Vulgaris
2003	A Randomized, Evaluator Blind, Vehicle Controlled, Parallel Group Dose Ranging Study of the Safety and Efficacy of Four Concentrations/Application Frequencies of Topical Cream Versus Its Vehicle in the Treatment of Plaque Psoriasis
2003	A Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Three Dose Levels of Oral Medication in the Treatment of Chronic Plaque Psoriasis
2002	A Multicenter, Randomized, Double-Blind, Double-Dummy Parallel Group Study to Assess the Efficacy, Safety and Tolerability of New Oral Formulation in Patients with Onychomycosis
2002	An Open Label Safety and Efficacy Study of Brand Name Drug To Assess Pigmentary Changes in Ethnic Groups of Asian, Latin/Hispanic and African American Descent with Skin Types II-IV
2002	A Phase 3, Vehicle Controlled Study of Topical Brand Name Gel Applied 3 Times per Week for 3 Weeks for Each Recurrence of Herpes Genitalis over 12 Months
2002	A Pilot Study to Evaluate Efficacy of 3 Different Nail Conditioners In Improving the Appearance of the Fingernail
2002	A Phase 3, Vehicle-controlled Study of Topical Brand Name Gel applied 2 times per Week for 2 Weeks for Each Recurrence of Anogenital Herpes over 12 months
2001 – 2002	A Vehicle-Controlled, Randomized, Double-Blind Multicenter Study of the Efficacy and Safety of Brand Name Shampoo in the Treatment of Seborrheic Dermatitis of the Scalp

- 2001 – 2002 A Randomized, Double-Blind, Placebo controlled Study of the Safety, Efficacy and Systemic Absorption of a Brand Name Topical Patch in the Treatment of distal Subungual Onychomycosis of the Great Toenail.
- 2001 A Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Bioequivalence of Sponsors Generic Shampoo and Brand Name Shampoo in Subjects with Tinea Versicolor
- 2001 Vehicle-Controlled, Modified-Blind, dose-Escalating Study to Assess Safety and Efficacy of Topical Gel for the Treatment of Common Warts in Adults
- 2001 A 24-Week Controlled Clinical Study to Evaluate the Efficacy of Brand Name Gel Compared to Placebo Gel in the Treatment of Tinea Pedis
- 2001 – 2002 A Multi-Center, Phase 3 Double Blind Study of Photodynamic Therapy (PDT) with Brand Name Cream in Comparison to PDT with Placebo Cream in Patients with Primary Nodular Basal Cell Carcinoma
- 2001 A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Determine the Therapeutic Equivalence of Two Cream Formulations in the Treatment of Rosacea
- 2001 A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Determine the Therapeutic Equivalence of Two Topical Formulations in the Treatment of Interdigital Tinea Pedis
- 2001 – 2002 A Vehicle-Controlled, Double Blind Study to Assess the Safety and Efficacy of Topical Cream for the Treatment of Superficial Basal Cell Carcinoma
- 2000 – 2002 A Phase 3, Vehicle Controlled Study of Topical Gel Applied Two Times per Week for Three Weeks for Each Recurrence of Herpes Genitalis over 12 months (US)
- 2000 – 2001 A Double-Blind, Randomized, Placebo-Controlled, Multi-Center to Investigate the Efficacy and Safety of Brand Name Spray Powder in Subjects with Tinea Pedis (Interdigital Type)
- 2000 – 2001 Post Treatment Maintenance and Follow-Up of Previous Protocol Evaluating the Efficacy and Safety of Name Brand Nail Gel in the Treatment of Mild to Moderate Distal Subungual Onychomycosis
- 2000 – 2002 Long Term (12 month) Safety and Efficacy of Brand Name in the Treatment of Melasma of the Face
- 2000 Efficacy and Safety of Brand Name Topical Therapy for the Treatment of Patients with Cutaneous Melanosis of the Face
- 2000 Open-Label Study of Brand Name Topical Therapy Combined with Cryotherapy for the Treatment of Common Warts
- 2000 – 2001 A One-Year Follow-Up Study to Clinically Validate the Histologic Endpoint for Patients who have completed the Nodular Basal Cell Carcinoma Study

2000	A One-Year Follow-Up Study to Clinically Validate the Histologic Endpoint for Patients who have Completed the Superficial Basal Cell Carcinoma Study
2000	Assessment of Clinical Efficacy, Safety, and Tolerance of Brand Name Drug vs. Brand Name Drug for Treatment of Skin and Skin Structure Infections in Children 5-17 years of age
2000	An Open-Label Study to evaluate the Effect of a Single Course of Brand Name Therapy in Bone Mineral Density in Pediatric Patients with Severe, Recalcitrant, Nodular Acne
2000	A Randomized, Double-Blind, Placebo-controlled, Dose-comparison Study to Evaluate The Efficacy and Safety of Intramuscular Medication in subjects with chronic Plaque Psoriasis
2000	Multi-center, double-blind, Randomized, Vehicle-controlled, Parallel-Group Study, To Determine the Therapeutic Equivalence of Two Drug formulations in the Treatment of Tinea Pedis
2000	The Safety and Efficacy of Brand name lotion as compared to its Vehicle and Brand Name Emollient Cream in the Treatment of Moderate to Severe Plaque-Type Psoriasis
1999	A Randomized, Placebo Controlled, Multi-Dose, Double-Blind Study of the Efficacy of Terbinafine HCI Cream, 1% for the Prophylactic Treatment of Tinea Pedis
1999	A Multicenter, Double-Blind Study of Evaluate Drug and Placebo in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail
1999	A Randomized, Double-Blind, Placebo-Controlled Pilot to Evaluate the Safety and Efficacy of 56 Days of Drug for the Treatment of Papular-Pustular Rosacea
1998 – 1999	A Prospective, Open Label, Multi-Center, Evaluation of Short Duration Therapy with Drug in the Treatment of Diabetic Subjects with Tinea Cruris/Corporis
1998 – 1999	A Prospective, Open Label, Multi-Center, Evaluation of Short Duration Therapy with Drug in the Treatment of Diabetic Subjects with Tinea Pedis
1998 – 1999	A Prospective, Open Label, Multi-Center, Evaluation of Short Duration Therapy with Drug in the Treatment of HIV Subjects with Tinea Cruris/Corporis
1998 – 1999	A Prospective, Open Label, Multi-Center, Evaluation of Short Duration Therapy with Drug in the Treatment of HIV Subjects with Tinea Pedis
1998 – 1999	A Randomized, Multicenter, Placebo-Controlled, Double-Blind Study of Drug for Treatment of Tinea Pedis
1998 – 1999	Vehicle-Controlled Dose Ranging Study of Drug for the Treatment of Plantar Warts
1998 – 1999	Vehicle-Controlled Dose Ranging Study of Drug for the Treatment of Common Warts
1998 – 1999	A 12-Week Dose Optimization Trial Evaluating Drug and Vehicle for the Treatment of Nodular Basal Cell Carcinoma

- 1998 – 1999 A 12-Week Dose Optimization Trial Evaluating Drug and Vehicle for the Treatment of Superficial Basal Cell Carcinoma
- 1998 – 1999 An Evaluator-Blinded, Randomized Study to Evaluate the Efficacy and Safety of Study Drug versus Comparison Drug as Treatments for *Pediculus humanus* variant *capitus* Infestation
- 1998 – 1999 A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy of Drug for the Treatment of Moderate Acne
- 1997 – 1998 A Multi-Centered Controlled, Double-Blind, Comparative Study of the Safety and Efficacy of Test Drug Vs Name Brand Drug and their Vehicles
- 1997 – 1998 A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy of Drug for the Treatment of Moderate Acne
- 1997 – 1998 A Double-Blind, Placebo-Controlled, Dose-Ranging Clinical Evaluation of Study Drug and Approved Drug in Subjects with Male Pattern Baldness
- 1997 – 1998 A Multi-Centered Controlled, Double-Blind, Comparative Study of the Safety and Efficacy of Investigational Acne Drug Vs Brand Name Acne Drug and Their Vehicles
- 1997 – 1998 A Randomized, Double-Blind, 12-Week, Multi-Center Clinical Trial to Determine the Bioequivalence of Two Formulations of Drug and Placebo in the Treatment of Moderately Severe Acne Vulgaris
- 1997 – 1998 A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of Drug 2% Cream in Patients with Interdigital Tinea Pedis
- 1997 – 1998 A Multicenter, Double-Blind Study to Evaluate the Safety and Efficacy of Drug in the Treatment of Tinea Pedis.
- 1996 – 1998 A Multicenter, Double-Blind Study to Evaluate 5% and 8% Drug Nail Product in the Treatment of Distal Subungual Onychomycosis of the Toenail.
- 1996 – 1997 A Multicenter, Double-Blind, Parallel-Group, Multiple oral Dose Study to Evaluate the Tolerability and Efficacy of Drug Versus Drug Versus Placebo in the Treatment of Patients With Moderate to Severe chronic Plaque-Type Psoriasis.
- 1996 – 1997 A Prospective, Multicenter, Open-Label Evaluation of 12 Weeks Therapy with Oral Drug in the Treatment of Onychomycosis of the Toenails in Diabetes Mellitus Patients with a Dermatophyte Infection.
- 1996 – 1997 A Double-Blind, Placebo-Controlled Study to Determine the Effect of Drug on Hair Growth in Men with Androgenetic Alopecia Using a Phototrichogram Technique.
- 1995 – 1996 A Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of 150, 300, 450 mg Weekly Doses of Drug in Patients with Distal Subungual Onychomycosis of the Toenail

- 1995 – 1996 A Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of 150, 300, 450 mg Weekly Doses of Drug in Patients with Distal Subungual Onychomycosis of the Fingernail
- 1995 – 1996 An Open-Label, Multicenter Trial to Evaluate the Safety and Effectiveness of Various Treatment Durations of Drug in Patients with Onychomycosis of the Toenails
- 1995 – 1996 A Double-Blind, Placebo-Controlled, Multicenter Study to Determine the Effect of Drug in Postmenopausal Women with Androgenetic Alopecia
- 1994 – 1996 A Double-Blind, Placebo-Controlled, Multicenter Study to Determine the Effect of Drug on Hair Loss in Men with Androgenetic Alopecia
- 1993 – 1996 A Double-Blind, Placebo-Controlled, Multicenter Study to Determine the Effect of Low Doses of Drug on Hair Loss in Men with Androgenetic Alopecia
- 1992 – 1996 A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Determine the Effect of Drug on Hair Loss in Male Patients with Androgenetic Alopecia
- 1992 – 1994 A Double-Blind, Randomized, Placebo Controlled, Multicenter Study to Determine the Safety of Topical Drug with Penetration Enhancer in the Treatment of Females with Androgenetic Alopecia

Invited Lecturer Presentations:

Upcoming:

MauiDerm, January 2024

AAD, March 2024

Completed:

MauiDerm, September 27-30, 2023, Nail Disorders.

Pacific Dermatology Association, July 28-30, 2023, Management of Nail Disease.

MauiDerm, June 21-24, 2023, Nailing the Diagnosis.

MauiDerm Hawaii, January 23-27, 2023, Workshop: Nail Disorders Diagnostic and Therapeutic Approaches to Nail Diseases.

MauiDerm Caribbean, January 11-14, 2023, Nailing The Diagnosis and Q&A.

International Conference on Nail Disorders, December 14-15, 2022, Onychomycosis in Children – An Update *and* Gel Lacquer Polish- Mechanism of the Pathogenesis, Complications and Therapeutic Approach.

MauiDerm NP+PA Fall, September 18-21, 2022, Nailing The Diagnosis (120 minutes) *and* Nailing the Diagnosis (40 minutes).

MauiDerm, June 22-25, 2022, Diagnostic and Therapeutic Challenges and Workshop B: Nail Disorders, Diagnostic *and* Therapeutic Approaches to Nail Diseases.

AAD Annual Meeting, March 23-27, 2022. Medical and Surgical Management of Nail Disorders *and* An Evidence-Based Approach to Nails: Expert Management of Common Problems.

MauiDerm, January 24-29, 2022, Diagnostic and Therapeutic Challenges and Workshop B: Nail Disorders, Diagnostic *and* Therapeutic Approaches to Nail Diseases. MauiDerm, September 29- October 2, 2021, Nailing the Diagnosis.

MauiDerm, June 23-26, 2021, Nailing the Diagnosis.

MauiDerm, January 25-29, 2021, Nail Disorders 2021: Diagnostic and Therapeutic Challenges *and* Workshop: Nail Disorders, Diagnostic and Therapeutic Approaches to Nail Diseases.

MauiDerm Connect, September 23-26, 2020, Virtual Meeting, Nailing the Diagnosis.

San Diego Dermatology Symposium, September 11-13, 2020, Virtual Meeting, Common Nail Disorders *and* Uncommon Nail Disorders.

MauiDerm, June 19-21, 2019, Nailing the Diagnosis (Master's Track) *and* Nailing the Diagnosis.

Oregon Health and Science University, June 11, 2020, presentation regarding nail disorders for current department of dermatology residents.

Florida Society of Dermatology Physician Assistants New Wave, April 16-19, 2020 Virtual Meeting, What You Need to Know About Nails.

MauiDerm, January 25-30, 2020, Nail Disorders 2020: Diagnostic and Therapeutic Challenges *and* Workshop B: Nail Disorders, Diagnostic and Therapeutic Approaches to Nail Disease

International Conference on Nail Disorders, December 3-4, 2019, Gel Lacquer Polish- Complications and Outcomes *and* Onychomycosis in Children- an Update.

MauiDerm NP+PA, October 2-5, 2019, Nailing the Diagnosis (long) *and* Nailing the Diagnosis.

Texas Dermatologic Society, September 28, 2019, What You Need to Know About Nails.

World Congress of Dermatology, June 11, 2019, Nail Surgery: State of the Art *and* Nail Update.

MauiDerm, June 19-21, 2019, Nailing the Diagnosis (long) *and* Nailing the Diagnosis.

AAD, March 4, 2019, Forum Director: F117- Medical and Surgical Management of Nail Disorders.

Council For Nail Disorders, February 28, 2019, Movies: Ingrown Nail Treatment, Chemical.

MauiDerm, January 29-30, 2019, Nail Disorders: Diagnostic and Therapeutic Approaches to Nail Disease *and* Workshop B: Nail Disorders: Diagnostic and Therapeutic Approaches to Nail Disease.

American Society for Dermatologic Surgery, October 11-14, 2018: Nail Surgery Techniques.

MauiDerm, September 29, 2018, Nailing the Diagnosis.

Pacific Dermatology, August 2-5, 2018, Common Nail Disorders: Soup to Nuts *and* Common Nail Disorders: The Lightning Round.

MauiDerm, June 20-23, 2018: Nailing the Diagnosis *and* Nails: Diagnostic and Therapeutic Challenges.

Samaritan Health Services, May 14, 2018: Diseases of the Fingernails and Toenails.

Massachusetts Grand Rounds, March 5, 2018: Diagnostic and Therapeutic Challenger of Nail Disorders.

AAD, February 16-20, 2018: S013 My Great Nail Case That Taught a Lesson *and* W012 Hands-on: Nail Surgery *and* F092 Medical and Surgical Management of Nail Disorders (session moderator).

Dermatology Nurses' Association, February 16, 2018: Nail Diagnosis, Therapy and Surgery: Cases.

Council for Nail Disorders, February 15, 2018: Is This Blood or Melanin *and* Treat Nail Psoriasis.

MauiDerm, January 29-February 2, 2018: Nail Disorders: Diagnostic, Therapeutic, and Surgical Approaches to Nail Diseases *and* Nail Disorders.

Fall Clinical, October 15, 2017: Nail Pearls.

Coastal Dermatology, October 6, 2017: Nailing Nail Disorders.

MauiDerm NP+PA, September 15, 2017: Nails: Diagnostic and Therapeutic Challenges.

World Congress Pediatric Dermatology, July 8, 2017: Uncommon Nail Problems in Children.

4th International Summit on Nail Disease, June 24-25, 2017: Symposium chairperson for Nail Cosmetics: the latest of new "no-light" gel nail enhancements *and* presentation: Why doesn't nail psoriasis scar the nail and nail lichen planus does?

Maui Derm NP+PA, June 14-16, 2017: Nailing the Diagnosis *and* Nails: Diagnostic and Therapeutic Challenges.

Maui Derm, March 22, 2017: Workshop B: Nail Disorders: Diagnostic, Therapeutic, and Surgical Approaches to Nail Diseases.

AAD, March 5-6, 2017: S044 Nails *and* W012 Hands-on: Nail Surgery *and* F140 Medical and Surgical Management of Nail Disorders.

Generational Dermatology, February 18, 2017: Generational Nail Psoriasis and Other Disorders.

Winter Clinical, January 18, 2017: Nail Tips.

IDEOM, October 15, 2016: Explanation of PASI scoring for psoriasis.

Maui Derm Fall Meeting, September 27-October 1, 2016: Nailing the Diagnosis *and* Nails: Diagnostic and Therapeutic Challenges.

Maui Derm PA+ NP, June 14-17, 2016: Nailing the Diagnosis *and* "Nails: Diagnostic and Therapeutic Challenges.

Aesthetic & Medical Dermatology Symposia, May 21-22, 2016: Hair & Nails- What's New.

Tulane Dermatology All That Jazz Update, April 20-23, 2016: Update on Nail Psoriasis *and* Nails- What's New.

AAD Annual Meeting, March 5-8, 2016: Nail Cosmetics: Best Practices for Safety *and* An Evidence-Based Approach to Nails: Expert Management of Common Problems *and* Nail Tumors: Benign and Malignant *and* Workshop: Hands-on: Nail Surgery.

Generational Dermatology Symposium, February 12-15, 2016: Nail Disorders.

Maui Derm Annual Meeting, January 24-28, 2016: Workshop: Nail Disorders: Diagnostic, Therapeutic, and Surgical Approaches to Nail Diseases.

Winter Clinical, January 15-20, 2016: Nail Tips.

Third International Summit for Nail Disease, New Delhi, India, November 11-22, 2015: Interesting Nail Cases from Across the Globe *and* Non-melanocytic melanonychia *and* Nail Cosmetics.

Maui Derm NP+PA Fall Meeting, September 15-18, 2015: Nail Surgery Workshop *and* Nails: Diagnostic and Therapeutic Challenges.

Colorado Dermatologic Society Annual Meeting, September 11, 2015: Nails: Diagnostic and Therapeutic

Challenges.

Maui Derm NP+PA Summer Meeting, June 24-26, 2015: Nail Surgery- video and discussion of nail biopsy *and* surgery techniques *and* Didactic nail workshop: Diseases and Tumors of the Nail (Masters Workshop) *and* Nails: Diagnostic and Therapeutic Challenges.

World Congress of Dermatology, June 10, 2015: Workshop, Nail Surgery.

Aesthetic + Medical Dermatology Symposia, May 15-16, 2015: Techniques for optimal skin cleansing *and* Rosacea management update *and* Update on nail disease and treatment *and* Update on hair disease and treatment.

Dermatology Nurses Association Annual Meeting, April 25, 2015: Medical and Surgical Management of Nail Disorders.

AAD Annual Meeting, March 21, 2015: Directing forum F079: Medical and Surgical Management of Nail Disorders.

Winter Skin Seminar, January 23-27, 2015: Nail Biopsies: When, Why, and How *and* Onychomycosis and Other Common Nail Problems.

Orlando Derm/Aesthetic Conference: January 17-18, 2015: Diagnosing and Treating Nail Disorders at Any Age *and* Therapeutic Advances in Fungal and Nail Infection Management.

Portland PA/NP: November 8, 2014: Nail It: Great Nail Cases.

Women's and Pediatrics Derm: October 10-11, 2014: Onychomycosis and Nail Disease *and* Pediatric Nail Abnormalities

Summer AAD: August 7, 2014: Update: Nail Surgery

Society for Pediatric Dermatology: July 11, 2014: Nail it! Pediatric Nail Cases

Maui Derm NP+PA Summer 2014: June 27, 2014: Nail Diagnostic and Therapeutic Challenges *and* Nail Disorders

Texas Dermatological Society Meeting: May 3, 2014: Medical and Surgical Management of Common and Challenging Nail Disorders *and* Nail Cases from the Pacific NW

Georgia Dermatology Physician Assistants: April 5, 2014: Dystrophic Nails: Evaluation and Management

Annual AAD meeting: March 21, 2014: Medical and Surgical Management of Nail Disorders *and* Evidence-Based Approach to Nails: Expert Management of Common Problems *and* Nailing Onychomycosis

Council for Nail Disorders: March 20, 2014: Brittle Nails

Hawaii Dermatology Seminar: February 16, 2014: Current and Emerging Options in the Treatment of Onychomycosis

Israeli Society of Dermato-Mycolological and Nail Disorders: December 18, 2013: What's New in Nail Cosmetics

North American Live Nail Surgery Course OHSU: September 6-7, 2013: Director of Course.

Summer AAD: August 4, 2013: Nail Surgery update; Medical and Surgical Management of Nail Disorders *and* Nail Cosmetics: New Variants *and* Update: Nail Cosmetics

Pacific Northwest Dermatological: July 12, 2013: Nails

Moroccan Society of Dermatology: April 5, 2013: Cosmetic care of the nail; News in nail lacquers *and* Psoriasis; Systemic treatment from old to biologics

Annual AAD: March 1-5, 2013: An Evidence-Based Approach to Nails: Expert Management of Common Problems *and* Dermatology Review: Nail Update *and* My Best Case *and* Course Director, Medical and Surgical Management of Nail Disorders *and* Nail Therapeutics.

Winter Clinical: January 23, 2013: Pearls in the Treatment of Nail Disease

Netherlands Nail Symposium: November 30, 2012: Evaluation and Treatment of Psoriatic Nail Disease

Family Medicine OHSU Residents: November 21, 2012.

PA Derm Conference: November 1, 2012: Update on Nails *and* Interesting Nail Cases.

EADV, Prague: September 26, 2012: Nail Tips

Summer AAD: August 17, 2012: Update on Nail Psoriasis *and* Forum Director: Nail Surgery

Wisconsin Dermatology Society: July 22, 2012: Nail Surgery: Practical Tips *and* Clinical Aspects of Nail Disease

3rd World Psoriasis & Psoriatic Arthritis Conference: June 30, 2012: Evaluation and Treatment of Psoriatic Nail Disease

AAD Annual Meeting: March 16-20, 2012: Nail Therapeutics *and* Melanonychia and Nail Unit Melanoma *and* Dermatology Review Director: Update on Nails.

Maui Derm: February 5, 2012: 20 Nails in 30 Minutes: Your Diagnostic and Therapeutic Acumen Will Be Challenged.

ASDS: November 4, 2011: Surgery of the Nail: Hammering Down your Technique

Fall Clinical Dermatology Conference: October 30, 2011: Managing the Nail Patient

PDA: August 11, 2011: Top 10 Nail Tips.

Summer AAD Meeting: August 4, 2011: Director, Nails Forum

World Congress of Dermatology: May 29, 2011: Director of Nail Surgery Workshop

Dermatology Nurse's Association: March 18, 2011: 10 Nail Tips Not to Gloss Over.

AAD Annual Meeting: February 7, 2011: Director: Dermatology Review *and* Symposium Director, Nails.

Winter Clinical: January 19, 2011: Great Nail Cases

AAD Annual Meeting: March 5, 2010: New Treatments for Nail Psoriasis *and* Forum: Fungal Infections *and* Forum: Clinical Mycology

AAD Annual Meeting: February 1-5, 2008: Nail Surgery *and* Director- Nails Forum.

DF Clinical Symposia: 2008: The Surgical Approach to Nail Disorders

World Congress of Dermatology: 2007: Update on Nail Cosmetics

AAD Summer Meeting: August 1-5, 2007: Nail Surgery, Women's Dermatology Forum, *and* Nails.

California Dermatology Annual Meeting: 2007: Five Nail Tips Not to Gloss Over

AAD Summer Meeting: July 26-30, 2006: Nails.

AAD Annual Meeting: 2007: Nail Surgery, Nail Symposia

Pacific Northwest Dermatology: 2006: Nail Review

AAD Summer Meeting: July 26-30, 2006: Nails.

AAD Annual Meeting: March 3-7, 2006: Nails *and* Update on Nail Cosmetics, *and* How to Have a Successful Medical & Cosmetic Practice.

AAD Summer Meeting: July 20-24, 2005: Nails.

AAD Annual Meeting: February 18-22, 2005: Update: Nail Cosmetics.

AAD Summer Meeting: July 31-August 4, 2002: Nail Cosmetic Update.

AAD Summer Meeting: July 28-August 1, 2001: Nail Cosmetics.

AAD Annual Meeting: March 2-7, 2001: Nail Surgery *and* 3 Best Managements of Nail Psoriasis.

AAD Summer Meeting: August 2-6, 2000: Nail Cosmetic Pearls & Update *and* Nail Surgical Pearls & Tips.

AAD Annual Meeting: March 10-15, 2000: What Systemic Drugs Affect the Nails? *and* Nail Surgery.

AAD Summer Meeting: July 28-August 1, 1999: Nail Disorders.

AAD Annual Meeting: February 27-March 4, 1998: The Brittle Nail Syndrome: What Is It? Etiology & Management *and* Director- Management of Common Nail Disorders.

AAD Annual Meeting: March 21-26, 1997: Nail Psoriasis: News & Views.

AAD Summer Meeting: July 24-28, 1996: Nail Disorders.

AAD Annual Meeting: February 10-15, 1996: Onychomycosis: New Drugs & Strategies for 1996.

This page is a manifestation of an electronic record that was signed electronically.

Document Name: CV Phoebe Rich, MD- Version 07Feb2024

Document ID: 28147

No. Pages: 59

Statement of Testament: I have reviewed and approve the document

Electronic Signature for: Phoebe Rich, MD

Electronically Signed by: prich

Date & Time: 08/FEB/2024 8:37:07 AM PST

IP Address: 96.95.149.205